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Optimizing rare variant association studies in theory and practice 
 
ABSTRACT 
 Genome-wide association studies (GWAS) have greatly improved our understanding of the 
genetic basis of complex traits. However, there are two major limitations with GWAS. First, 
most common variants identified by GWAS individually or in combination explain only a small 
proportion of heritability. This raises the possibility that additional forms of genetic variation, 
such as rare variants, could contribute to the missing heritability. The second limitation is that 
GWAS typically cannot identify which genes are being affected by the associated variants. 
Examination of rare variants, especially those in coding regions of the genome, can help address 
these issues. Moreover, several studies have recently identified low-frequency variants at both 
known and novel loci associated with complex traits, suggesting that functionally significant rare 
variants exist in the human population. 
However, without sufficiently large sample size, we are underpowered to detect rare 
variant effects due to the low allele frequencies and the large numbers of rare variants in the 
exome. This dissertation is broadly divided into two parts to explore strategies for optimizing the 
power of rare variant association studies. First, we developed a cost-efficient pooled sequencing 
scheme as well as the analytic framework that ensures low false positive and false negative rates 
in variant discovery. We showed that this strategy is good for follow-up studies of candidate 
genes and for identifying potential genetic diagnosis in well-phenotyped patients. Second, we 
employed forward simulation to assess the usefulness of founder populations in rare variant 
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association studies and compare the efficiency of exome array genotyping vs. high coverage 
exome sequencing. We developed a novel simultaneous simulation of sequence variation in the 
non-Finnish European and the Finnish population that closely approximates the empirical 
sequence data. We showed that studies of founder populations like Finland can substantially 
increase power for discovery in a subset of genes and exome chip is currently much more 
cost-efficient than exome sequencing. Taken together, our results have highlighted the usefulness 
of having diverse sets of populations (ideally founder populations) and employing cost-efficient 
study designs such as exome chip followed by pooled sequencing to boost power of rare variant 
association studies. 
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Chapter 1 
 
Introduction 
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A PREAMBLE 
 Genetic studies have revealed thousands of loci contributing to common polygenic human 
diseases and traits. Studies to date have mostly focused on studying individual common variants, 
because they could be more readily assayed with initial genomic technologies. Nonetheless, the 
genetic variants discovered thus far typically explain only a small fraction of the estimated 
heritability. Some of the so-called missing heritability is likely due to additional common 
variants yet to be discovered. On the one hand, studies have been limited by sample size; those 
with larger sample sizes continue to reveal many new loci1–3. On the other hand, indirect 
statistical methods indicate that common variants collectively capture at least 30% (and likely 
more) a large proportion of the heritability for a number of diseases and traits4–6.  
The additional sources of missing heritability remain unclear. One hypothesis is that much 
of the missing heritability is due to rare genetic variants. The theoretical case for an important 
role of rare variants is that alleles predisposing to disease are likely to be deleterious and thus 
kept at low frequencies by purifying selection7–9. Because rare variants are too numerous and 
occur too infrequently, rare variant association studies (RVAS), like common variant association 
studies (CVAS)10, would require large sample collections and careful statistical analysis to 
achieve adequate power to detect genes underlying diseases.  
In reality, the practice of RVAS is still in its infancy. Some early efforts were premised on 
the notion that rare variants underlying common diseases could be readily identified in small 
numbers of samples. The few discoveries from RVAS thus far are mostly from candidate gene 
studies rather than unbiased gene discovery and, in some cases, reach only nominal rather than 
genome-wide levels of significance11–18. The analytical methodology for RVAS remains in flux, 
although many groups have proposed a rich collection of possible statistics19–21.   
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To address these challenges, in this dissertation we present an initial attempt to evaluate the 
design of RVAS and explore strategies for maximizing power of RVAS. In Chapter 2, we will 
describe a cost-efficient pooled sequencing scheme, which is further illustrated by applications 
of it in both Chapter 2 and Chapter 3. In Chapter 4, we present an analytical framework for 
evaluating the design of RVAS in different study populations. As the field of human genetics 
moves forward to explore expanded sources of variation in more diverse populations, we believe 
our approach will be useful to guide future studies. 
 However, before describing the results and implications of each chapter, a more thorough 
introduction to human genetic analysis is warranted. As such, the remainder of this chapter is 
broadly divided into three sections. The first section provides an overview of complex trait 
genetics, including the approaches for mapping genes underlying a phenotype of interest. The 
second section reviews the approaches for studying human complex traits, describing the process 
from early linkage studies to genetic association studies of both common and rare variants. The 
third section is a brief introduction to pooled sequencing and its limitations and challenges.  
 
GENETICS OF COMPLEX TRAITS 
 Interest in the genetic basis of disease originated with the rediscovery of Mendel’s laws in 
the beginning of the 20th century. Subsequent studies have identified many of the genes 
responsible for Mendelian diseases, conditions that are strongly influenced by highly penetrant 
variants in a single locus and follow a clear familial pattern. While Mendelian traits formed the 
basis for classic genetics, it has become clear that most common human traits and diseases are 
complex traits, influenced by many genetic loci, along with environmental factors. Examples 
include cardiovascular, metabolic and neuropsychiatric disorders.  
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While most alleles underlying Mendelian diseases are rare and relatively new in the 
population, controversy exists regarding the likely allelic spectrum of variants contributing to 
complex traits. Two major lines of reasoning, representing two extremes of the frequency 
spectrum of variants, exist: the “common disease common variant” hypothesis and the “common 
disease rare variant” hypothesis. 
 
The common disease common variant hypothesis 
At one extreme, the “common disease common variant” hypothesis (CDCV hypothesis) 
posits that common genetic variants underlie susceptibility to most common traits. This 
hypothesis is rooted in the assumption that the majority of polymorphisms predisposing to 
complex diseases are not evolutionarily deleterious and thus can rise to high frequencies. Several 
evolutionary scenarios might explain why disease-causing variants escape purifying selection, 
such as positive or balancing selection22, a late disease onset, and changing direction of 
selection23. To date, genome-wide association studies have successfully identified thousands of 
common variants24, which to a certain extent supports the CDCV hypothesis. Examples of such 
common variants include the APOE ε4 allele in Alzheimer’s disease25 and PPARγ Pro12Ala in 
type II diabetes26.     
 
The common disease rare variant hypothesis 
On the other extreme is the “common disease rare variant” hypothesis (CDRV hypothesis). 
This model dictates that phenotypic variation in complex traits is caused by moderately highly 
penetrant rare variants. The key assumption here is that the majority of disease-causing 
mutations are also mildly evolutionarily deleterious and thus kept at low frequencies by 
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purifying selection. A high mutation rate counterbalances the action of purifying selection and 
determines the cumulative frequency of disease-causing variants9. A well-known example 
supporting this hypothesis is the BRCA1 and BRCA2 breast cancer susceptibility mutations. 
Women carrying mutations in these genes have a lifetime risk of breast cancer as high as 80%. 
Thousands of mutations have been found within these two loci; they are collectively quite 
common but individually rare or even private to the family27,28. 
 
Both models have been supported by earlier theoretical studies9,29,30. The difference in 
conclusions is mostly due to difference in the rate of deleterious mutations and the strength of 
selection against new mutations7. In reality, the dichotomy between the two models might not be 
absolute. It is likely that both common and rare variants, along with interactions between variants 
both common and rare and interactions of genetic variants with the environment, contribute to 
complex traits. Neither model is likely to be exclusively accurate for any trait in general, and the 
genetic architecture and allelic spectrum of causal variants is likely to differ from trait to trait.  
 
APPROACHES FOR STUDYING HUMAN COMPLEX TRAITS 
 Having introduced the hypotheses regarding the genetic basis of complex traits, we next 
discuss the approaches that have been used to map genetic loci responsible for phenotypic 
variation. These approaches can be broadly grouped into two categories: linkage analysis and 
genetic association studies. Linkage analysis, a statistical technique that successfully identified 
casual genes for many Mendelian disorders, has had limited success for gene mapping of 
complex traits. An alternative is genetic association studies, which are analogous to traditional 
epidemiologic association studies. Instead of seeking association between traditional risk 
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variables and disease outcome, a genetic association study looks for an association between a 
genetic variant and a specified condition. 
 
Limited success of linkage analysis for complex traits 
 The principle of linkage analysis is founded on the co-segregation of chromosomal regions 
identical by descent along with the disease phenotype of interest within large families. 
Genome-wide linkage studies became feasible in the 1980s, with genome-wide linkage map of 
hundreds of DNA sequence variations31. Since the first successful demonstration of systematic 
linkage analysis to localize the gene causing Huntington disease in 198332, linkage analysis has 
led to the discovery of causal mutations for a large number of Mendelian disorders33. 
 Genome-wide linkage analysis has also attempted on a large number of complex traits. 
Despite the discovery of some clearly relevant loci that contribute to susceptibility of complex 
diseases such as inflammatory bowel disease34,35 and type 1 diabetes36, most of these studies 
have failed to identify a locus by strict criteria37 and the results of studies of the same disease are 
often inconsistent38. The reasons for this lack of success can be ascribed to a few basic problems. 
First, mutations in any one of multiple genes may result in identical phenotypes (locus 
heterogeneity). Genetic heterogeneity hampers linkage analysis, because a chromosomal region 
may co-segregate with a disease in some families but not in the others. Second, some traits may 
require multiple variants to act in concert (polygenic inheritance). Polygenic inheritance would 
complicate linkage analysis because no single locus is strictly required to cause a disease. Third, 
loci underlying complex traits each likely have much smaller effects (i.e., reduced penetrance), 
each potentially also interacting with other genes or environment. Thus, the genotype at a given 
locus may affect the probability of disease, but not fully determine the outcome. In such cases, 
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the signal-to-noise ratio is reduced in a linkage analysis, making it harder to pinpoint a linked 
region38–42. Moreover, linkage analysis has very low resolution. Even if a chromosomal region 
can be definitively mapped, the linkage peak region often covers several megabases. Therefore, 
extensive candidate gene studies are still required to narrow analysis to the causal gene or genes 
in the linked region42,43. 
 
The principles of association studies 
 An alternative approach to identify the genetic basis of complex traits is population-based 
association studies. Association studies assess the correlation between genetic markers and trait 
differences among unrelated population samples. The aim is to track the small chunk of ancestral 
chromosome where the causal mutation first arose but have decayed over time due to 
recombination. A higher frequency of a genetic marker in individuals with a disease can be 
interpreted as meaning that the tested marker increases disease risk. Genetic markers and trait 
can also become associated by other mechanisms, among which linkage disequilibrium (LD) is 
of greatest interest. The human genome is composed of long “block-like” regions where SNPs 
are non-randomly associated with one another, a phenomenon known as LD44–46. If the 
genotyped marker is in LD with the causal variant, the genotyped marker would also appear to 
be associated with the phenotype, and allows localization of the genetic locus. In essence, 
association studies and linkage analysis are quite similar, both relying on the co-segregation of 
chromosomal regions that contain both the genetic marker and the disease locus. They differ in 
that linkage analysis tracks chromosomal regions over a few generations of recent ancestry, and 
association studies track smaller chromosomal regions over many generations of historical 
ancestry. 
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 Despite the similarity in fundamental principles, association studies have greater statistical 
power to detect relatively common alleles with modest effect sizes than linkage analysis, 
requiring fewer (although still a large number) individuals in the study47,48. The large number of 
individuals required for a powerful study design in either scenario also means that it is easier to 
conduct a powerful association study as it is relatively easier to recruit unrelated affected 
individuals than to collect large numbers of pedigrees each with multiple affected individuals, 
particularly for diseases of old age43. In addition, association studies have higher resolution than 
linkage analysis, because the region around a marker shared identically by descent in unrelated 
individuals will be much smaller than the shared region between family members43,47. 
 There are different ways in which association studies can be categorized. Regarding the trait 
of interest, there are case-control studies for dichotomous phenotypes and population-based 
studies for continuous quantitative traits. Regarding the scale of the study, there are two broad 
categories: candidate-gene studies and genome-wide studies. Regarding the frequency spectrum 
of tested variants, association studies could evaluate common variants or rare variants. 
Association studies of individual common variants are named as genome-wide association 
studies (GWAS), whereas association studies of rare variants are often described as resequencing 
studies. This nomenclature conflates statistical methodology (association testing) and laboratory 
methodology (DNA sequencing). We will use the terms from Zuk et al.10: common variant 
association study (CVAS) and rare variant association study (RVAS).  
 
CVAS: from candidate gene approach to genome-wide studies 
Association studies to date have largely focused on studying individual common variants. 
Early CVAS had typically taken a candidate gene approach. Candidate genes are often selected 
 9 
based on potential biological relevance or from prior human genetic evidence42,43. Such studies 
have successfully identified a number of genes that contribute to susceptibility to common 
disease, such as PPARG and KCNJ11 for type 2 diabetes26,49 and ABCA1, APOA1, and LCAT for 
plasma levels of high-density lipoprotein cholesterol11. Nonetheless, the inherent problem with 
candidate gene approach is that it is limited by our understanding of the disease pathophysiology. 
Moreover, the significant findings of association in candidate-gene studies, which were typically 
not held to the current genome-wide threshold of significance (p<5x10-8) are often not 
consistently associated with disease across a large number of independent studies50,51. 
Aided by the dense genetic map from the HapMap project46 and the development of highly 
accurate, cost-efficient, SNP array technology, the paradigm in CVAS has largely shifted from 
candidate gene studies to genome-wide studies over the last few years. The basic scheme used is 
to catalogue very common variants and genotype them either directly or indirectly (through LD). 
Because no assumptions are made about the genomic location of the causal variants, the 
genome-wide approach could exploit the strengths of association studies without having to guess 
the identity of the causal genes. Today, millions of SNPs can be assayed by commercialized SNP 
arrays simultaneously. By properties of LD, these SNPs quite adequately cover most of the 
common variation in human populations, particularly for European-derived and East Asian 
populations due to their extended LD blocks52,53. Moreover, the remaining catalogued common 
variants not covered by the commercial arrays can be recovered by computational approaches 
known as imputation.  
 
The success and failure of CVAS 
 To date, CVAS have successfully identified thousands of common variants associated with 
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hundreds of diseases and traits54. These studies have “rediscovered” many genes that have been 
shown to be important. For example, of the 95 loci found to be associated with blood lipid levels, 
18 genes were previously implicated in Mendelian lipid disorders, and several others had been 
known to influence lipid metabolism55. These studies have also highlighted biological pathways 
previously not known to be relevant to a particular disease or trait. The loci associated with 
Crohn’s disease point unambiguously to autophagy and interleukin-23-related pathways56, and 
the height loci include genes encoding chromatin proteins and hedgehog signaling57. Finally, 
many new identified loci do not implicate genes with known functions. For these findings, 
greater effort will be required to generate hypotheses for future work, but such efforts could open 
new avenues of biological research of complex traits. For instance, a ubiquitin ligase, MYLIP, 
had no recognizable role in lipid metabolism before CVAS, but has since been shown to regulate 
cellular LDL receptor levels3,58.  
Despite the widespread success of CVAS in identifying genes and pathways relevant to 
complex traits, there are two major limitations. First, common variants identified by CVAS 
almost universally have small effects (~1.1 to 1.5 fold increased risk), and in combination 
explain a small proportion of the phenotypic variance attributable to genetic causes (the 
“heritability”)59–61. In the case of height, where heritability is as high as 80%, only ~10% of 
phenotypic variance is explained by currently published CVAS association signals2. Though 
using the mixed linear modeling approach over 50% of the phenotype can be attributed to 
common variants5, it can be argued that common variants do not capture the full range of genetic 
variance and that part of the missing heritability will need to be addressed with rare variants and 
broad sense heritability components such as gene-gene or gene-environment interactions62–64. 
Second, CVAS likely have not identified the causal SNPs, but rather have identified variants that 
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are proxies for the causal SNP or haplotype. Association signals often do not point 
unambiguously to a particular gene.  
The biologic pictures being revealed by CVAS are still quite incomplete. We should strive 
for as complete a catalogue of validated risk variants as possible. On the one hand, additional 
CVAS, in larger samples and multiple ethnicities, will continue to reveal many more new loci1–3 
and follow-up by approaches including fine mapping, genomic analysis of gene expression in 
human tissues, and screen for mutations on marker-containing haplotypes will lead to better 
understanding of the results. On the other hand, complementary approaches such as RVAS will 
look into additional sources of missing heritability. 
 
RVAS: sequencing and complementary approaches 
The frequency boundaries for defining rare variants in the literature vary. Here, we use 
minor allele frequency of less than 5%, as variants of this frequency range are poorly captured by 
the commercial arrays for genome-wide CVAS. Genome-wide surveys for such variants will 
eventually be carried out in a manner similar to CVAS, with very large sample sizes that will 
provide sufficient statistical evidence to implicate variants on the basis of association evidence 
alone.  
With the arrival of the next-generation sequencing technologies, it has come into reach to 
have full genomic sequences available for multiple individuals rather than relying on a more or 
less representative fraction of the genome. High-coverage whole-genome sequencing will be the 
method of choice once it becomes more affordable, with the rapid increase in the sequencing 
capacity of existing platforms, as well as the development of new, less-expensive platforms. 
However, in the interim, it will be important to focus on more cost-effective alternative strategies. 
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One popular approach is whole-exome sequencing. Because the most obvious 
disease-influencing variants will be the clearly functional ones, whole-exome sequencing is a 
much smaller, more cost-effective and more easily interpreted bundle. An even cheaper 
alternative approach is to use genotyping arrays which account for less common variants, an 
example of which is exome chip. In Chapter 4, we present a simulation-based work where we 
compared the power and cost-efficiency of exome chip against exome sequencing. Imputation of 
rare variants into samples with existing genotype data is another likely complementary approach 
for future studies, especially as reference panels for imputation become larger and represent 
more populations. 
 
Strategies for optimizing the power of RVAS 
Until sequencing studies are inexpensive enough to for large sample sizes, it will be 
important to focus on designs that are optimized to detect the role of casual variants in smaller 
samples. Such designs may accelerate progress, by enabling early discoveries. Applications of 
these designs can be seen in Chapter 2 and 3.  
First, isolated populations resulting from recent bottlenecks should make it easier to detect a 
subset of genes. Examples include Finland, Iceland, Ashkenazi Jews, Amish, Bedouins, and 
various endogamous groups in India. Studies across multiple such populations could prove 
valuable. In Chapter 4, we explore in depth the implication of founder effect in RVAS. 
Second, extreme-trait sequencing is likely to be another important engine of discovery. A 
basic extreme-trait design would be to sequence a small, carefully selected population at one or 
both ends of the extremes of a phenotype. Because variants that contribute to the trait will be 
enriched in frequency in the extreme individuals, even small sample sizes may suggest candidate 
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variants that can then be genotyped for confirmation in a much larger collection of samples. For 
the follow-up of variants identified in extreme-trait sequencing, family members of the extreme 
individuals will be invaluable for confirming potentially causal variants through co-segregation 
analysis.  
Third, early signals may be provided by the study of gene sets that are likely to be enriched 
for disease-associated loci. The best sets may consist of genes implicated by CVAS. Whereas 
CVAS and RVAS are sometimes thought of as alternatives, they are likely to be complementary. 
Targeted sequencing of pooled samples is well suited for studying candidate gene sets, which we 
will discuss in more detail below. 
 
POOLED SEQUENCING 
Motivations for pooled sequencing 
As opposed to the naïve approach that aims at sequencing large regions in a single 
individual, there are many biological applications wherein the sequence of a small region must 
be determined from many independent samples. Examples might include studies of variation 
within specific regions from a large population, looking for associations between variants and 
trait in areas that might have been narrowed by prior linkage analysis, CVAS, or even medical 
diagnostics. Use of next-generation sequencing technologies for interrogating sequence for any 
of these tasks is hampered if libraries must be constructed independently from each sample or if 
different barcodes must be applied to each sample prior to sequencing, particularly if sample 
numbers run into many thousands. 
The actual cost of sequencing a sample consists of two parts. The first part is the cost of 
preparing a DNA sample for sequencing which is referred to as library preparation cost. Library 
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preparation is also the most time-consuming and labor-intensive part of a sequencing study. The 
second part is the cost of the actual sequencing, which is proportional to the amount of sequence. 
The dramatic increase in the efficiency of the sequencing technology makes the costs of the 
sequencing step negligible for small target regions. Thus the main remaining cost is the sample 
preparation step. 
This limitation raises the need for the development of multiplexing strategies that allow 
the processing of multiple samples per single sample preparation step at the cost of requiring 
additional sequencing capacity. Pooled genotyping has been used to quantify previously 
identified variations and study allele frequency distributions65–67 in populations. Given an 
observed number of alleles and an estimate of the number of times an allelic region was sampled 
in the pool, it is possible to infer the frequency of the allele in the pooled individuals being 
studied. Pooled sequencing can be used to reach similar ends, as a strategy to cost-effectively 
capture all variation in a target region. Such an approach allows efficient use of next-generation 
sequencing technologies, as sequencing a large pool of individuals simultaneously keeps the 
number of redundant DNA reads low.  
 
Overview of pooling methods 
 
The basic idea behind pooled sequencing is that DNA from multiple individuals is pooled 
together into a single DNA mixture which is then prepared as a single library and sequenced. In 
this approach, the library preparation cost is reduced because one library is prepared per pool 
instead of one library per sample. 
Pooling methods can be split into two categories. The first category puts each individual in 
only one pool. The naïve, disjoint pooling scheme offers insight into allele frequencies, but does 
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not offer the identity of an allele carrier. These types of methods are referred to as 
non-overlapping pool methods. The second category puts each individual in multiple pools and 
uses this information to recover each individual’s genotype. These methods are referred to as 
overlapping pool methods. Many groups have developed sophisticated overlapping pooling 
designs, which encode the identity of each sample within the pooling pattern68–70. However, 
these designs usually involve complicated DNA pooling step. In our work, we developed a 
simple overlapping pooling design, which only allows decoding of singleton variants. But as we 
will show in Chapter 2 and 3, the singleton variants capture well the minor allele frequency 
range we aim to target in our studies. 
 
Limitations and challenges of pooled sequencing 
One obvious limitation of pooled sequencing is that haplotype information is not available. 
But this will be outweighed by the increased efficiency in studies where LD information is not as 
critical. Other major limitations include the ambiguous identification of individual carriers, 
especially in the presence of errors and difficulty in discerning whether a singleton variant is 
homozygous or heterozygous in an individual subject. 
SNP calling and estimating the frequency of the minor allele from pooled samples, is a 
subtle exercise for at least three reasons. First, sequencing errors may have a much larger 
relevance than in individual SNP calling. While their impact in individual sequencing can be 
reduced by setting a minimum number of reads per allele, this would have a strong and undesired 
effect in pools because it is unlikely that alleles at low frequency in the pool will be read many 
times71. Second, an obvious source of error in the pooling approach is the unequal representation 
of each sample’s DNA in the pool. This unequal representation could be due to human or 
 16 
machine error. In experiments that rely on PCR amplification, the heterogeneity can be expected 
to be particularly strong. Individuals for which a larger DNA amount has been included in the 
pool will be overrepresented, which potentially causes a change in allele frequency estimates, 
while unrepresented samples in pool might lead to false negative discoveries72. 
In Chapter 2, we present a simple matrix pooling design that overcomes some of these 
obstacles. Under this design, each sample was sequenced in 2 pools (1 row pool and 1 column 
pool), which allows us to identify individuals carrying singleton variants. Moreover, the matrix 
design is less affected by unequal representation of each sample’s DNA in the pool and enables 
us to filter out a lot of false positives from sequencing errors or other sources. In Chapter 3, we 
applied this approach to perform an RVAS of a particular gene (NPR2) where heterozygous 
mutations had been proposed to contribute to short stature.  
 
SUMMARY 
This introductory chapter hopefully has described and contrasted the major thoughts in 
human genetics research over the last 10-15 years, with a focus on using association studies to 
map disease genes. Aiming to provide the relevant background for the rest of this dissertation, 
we have compared and contrasted the common disease common variant and common disease 
rare variant hypotheses and discussed the methodology used to conduct an association study. We 
introduced the methodology of pooled sequencing and discussed its relative merits, setting the 
stage for the studies in Chapter 2 and 3. We also covered various strategies and designs for 
optimizing RVAS, which were evaluated under a simulation framework in Chapter 4. 
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ABSTRACT 
The majority of patients presenting with short stature do not receive a definitive diagnosis. 
Advances in genetic sequencing allow for large-scale screening of candidate genes, potentially 
leading to genetic diagnoses. The purpose of this study was to discover genetic variants that 
contribute to short stature in a cohort of children with no known genetic etiology. A total of 192 
children with short stature with no defined genetic etiology and 192 individuals of normal stature 
from the Framingham Heart Study were studied. Pooled targeted sequencing using 
next-generation DNA sequencing technology of the exons of 1077 candidate genes was 
performed. The numbers of rare nonsynonymous genetic variants found in case patients but not 
in control subjects, known pathogenic variants in case patients, and potentially pathogenic 
variants in IGF1R were determined. We identified 4928 genetic variants in 1077 genes that were 
present in case patients but not in control subjects. Of those, 1349 variants were novel (898 
nonsynonymous). False-positive rates from pooled sequencing were 4% to 5%, and the 
false-negative rate was 0.1% in regions covered well by sequencing. We identified 3 individuals 
with known pathogenic variants in PTPN11 causing undiagnosed Noonan syndrome. There were 
9 rare potentially nonsynonymous variants in IGF1R, one of which is a novel, probably 
pathogenic, frameshift mutation. A previously reported pathogenic variant in IGF1R was present 
in a control subject. In summary, large-scale sequencing efforts have the potential to rapidly 
identify genetic etiologies of short stature, but data interpretation is complex; Noonan syndrome 
may be an underdiagnosed cause of short stature. 
 
INTRODUCTION 
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Growth is a fundamental biological process that occurs during childhood. With the 
exception of diabetes, short stature is one of the most common reasons for referral to a pediatric 
endocrinologist. In most cases, short stature is familial, consistent with a strong genetic influence 
on childhood and adult height. In some cases, however, children have severe short stature that is 
out of proportion to the parental heights or have short stature associated with syndromic features. 
Molecular defects associated with these rarer cases have, over the last decade, expanded the list 
of genes and biological pathways known to influence growth. Multiple mutations, for example, 
have been found in the GH pathway, not only in the GH gene (GH1) itself, but also downstream 
within the GHR (GH receptor), STAT5B, IGF1, IGFALS, and IGF1R (IGF-I receptor) genes1. 
Many genes underlying severe skeletal dysplasias associated with short stature have also been 
identified2. Despite these advances, the molecular causality in the vast majority of patients, 
including those with severe or syndromic short stature, remains unresolved. Consequently, most 
affected patients continue to be classified as having idiopathic short stature. 
Genome-wide association (GWA) studies have enabled the identification of common 
genetic variants (frequencies >5%) influencing quantitative traits such as height. Indeed, recent 
GWA studies identified 180 genetic loci with common DNA sequence variants that influence 
human stature3. Intriguingly, these common variants are often located in or near genes that 
underlie syndromes of abnormal skeletal growth. This overlap suggests that rare variants in other 
genes highlighted by the GWA studies could have significant effects on growth. 
To explore the role of rare genetic variants in short stature, we developed and applied 
large-scale candidate gene sequencing technologies4 in a cohort of children with short stature of 
unknown cause. The selected list of 1077 candidates is composed of genes from identified GWA 
loci, genes known to cause syndromic short stature, and genes known to be involved in growth 
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plate biology or growth plate signaling. Herein, we report our initial screening and assessment of 
pooled exonic sequencing on DNA samples from 192 children with short stature and 192 control 
children of normal stature. We identified a large number of nonsynonymous variants present in 
case patients but not in control subjects. There are a number of possible analytical approaches to 
explore these data. First, one can search for variants that have previously been reported to be 
pathogenic. Second, one can search for novel variants within genes known to cause short stature 
and then perform further familial segregation and functional studies to validate those variants. 
Third, one can search for multiple likely deleterious variants in novel genes not previously 
known to cause short stature. In the current article, we discuss the first approach, looking for 
known pathogenic variants, and provide a more detailed analysis of rare genetic variants 
identified in IGF1R as an example of the second approach. Haploinsufficiency of IGF1R is 
known to cause significant short stature, and our data demonstrate the utility of large-scale 
sequencing and the critical need for careful interpretation of the resulting data. Future work will 
explore the other analytical approaches. 
 
RESULTS 
Description of cohort 
Participants in this study included 192 subjects (106 male and 86 female), 75% of whom 
were white. The height z scores ranged from −2.05 to −7.01 SD (Figure 2.1). The ages of these 
subjects ranged from 3 to 22 years with a mean of 10.3 years. Seventy subjects (36.4%) had 
begun GH therapy for short stature before enrollment in the study. However, GH deficiency was 
diagnosed in only 31 subjects (16%); of these, 22 had isolated GH deficiency without additional 
pituitary hormone defects. For those subjects receiving GH therapy, only height z scores before 
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initiation of therapy are shown (Figure 2.1). An additional 14 subjects were thought to have 
known genetic syndromes, but clinical diagnostic testing for the suspected syndromes had not 
identified pathogenic variants. Twenty-nine subjects were reported to have developmental delay. 
 
 
 
Figure 2.1: Height z score at enrollment or before initiation of GH therapy. Each bar 
represents individuals with a height z score less than or equal to the number noted below it on the 
x-axis but greater than the number below the bar to the left. For example, the right-most bar 
represents individuals with a height z score -2.25 < z ≤ -2. 
 
Validating pooled sequencing results 
Using our pooled sequencing design, the false-positive rate of singleton variants estimated 
by comparison to the exome data was 4.8% (range, 0%–12.5% per individual) (Table 2.1). In 
addition, a total of 7 singleton variants mapped to the 8 holes in the 2 matrices compared with 
7680 singleton variants that mapped to the 384 subjects (patients and control subjects), resulting 
in a similar estimation of the false-positive rate of 4.2%. These numbers establish the upper 
bound for the variant false-positive rate, because singleton variants are more likely to be false 
positives than variants found in multiple individuals. Of a total of 6618 variants present in the 6 
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exome samples within our target region, 7 variants were not identified by the pooled sequencing, 
giving an estimated overall false-negative rate of 0.1%. Similar to the false-positive rate, the 
false-negative rate for singleton variants is likely to be higher than that of other variants because 
singleton variants only appear in 2 pools and are more difficult to identify. 
 
Table 2.1: False-positive rate of singletons estimated by comparing with exome sequencing 
of 6 samples 

Sample No. No. of singletons False-positive singletons False-positive rate, % 
1 34 4 11.8 
2 58 1 1.7 
3 55 3 5.5 
4 15 0 0.0 
5 30 0 0.0 
6 16 2 12.5 
Summary 208 10 4.8 

Pathogenicity of rare variants 
In the 192 short stature patients, we identified a total of 10819 variants, of which 4928 were 
not detected in the control samples. Of these, 1349 were novel (Table 2.2). To screen for possible 
causal effects of variants found in our cohort, we compared these variants to those found in the 
Human Gene Mutation Database (HGMD)5. The database contains 26995 SNPs or indels located 
in the 1077 genes in our study, in which the variant has been reported as being associated with a 
particular clinical phenotype. We identified 66 such SNPs that matched a variant detected in our 
case subjects but not in control subjects. Because the HGMD is known to have erroneous entries, 
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we eliminated 7 variants with a minor allele frequency of ≥1% because these are unlikely to be 
true pathogenic variants. Of the remaining 59 variants, 32 were associated with recessive 
conditions or predispositions to complex traits, and the clinical pictures of the patients were not 
consistent with the disease phenotype, suggesting that they are unaffected heterozygous carriers. 
The final 27 variants previously associated with dominantly inherited diseases are listed in Table 
S2.1. We reviewed the phenotypes of the 27 case subjects and identified 1 case of autosomal 
dominant brachyolmia type 3 and 3 cases of Noonan syndrome. The remaining 24 case subjects 
did not have phenotypes consistent with the reported disease associations. 
 
Table 2.2: Variants identified in short stature samples but not in control samples 
 
Known variants Variant type 
ALL MAF<5% MAF<1% 
Novel variants 
Silent 1632 1602 1356 451 
Missense 1903 1888 1704 829 
Splice 11 11 10 8 
Indel 11 11 10 46 
Nonsense 22 22 22 15 
Total 3579 3534 3102 1349 
Abbreviation: MAF, minor allele frequency. 
 
Identification of pathological variants associated with brachyolmia and Noonan syndrome 
The patient with brachyolmia has a height of −3.88 SD and platyspondyly of the cervical 
spine. The mutation in TRPV4 is a missense mutation (c.1858G>A, V620I) that is a known 
variant causing the disease6. Before the research results became available but subsequent to 
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enrollment in our study, brachyolmia was clinically diagnosed in the patient, and clinical testing 
revealed this mutation. 
All 3 patients with Noonan syndrome carried variants in PTPN11, the most common 
causative gene in this syndrome. Noonan syndrome is an autosomal dominant condition with 
characteristic dysmorphic facial features as well as short stature, webbed neck, and cardiac 
abnormalities7. The first subject is an 11-year-old girl with a height z score of −2.7 SD. Isolated 
GH deficiency was diagnosed at age 7 years, and she had a poor response to GH therapy. Of note, 
she was born with a transitional atrioventricular canal defect, which was repaired at 4 months of 
age. She had a triangular face with a mildly low posterior hair line and slightly wide-spaced eyes. 
She did not have ptosis or downslanting eyes, and her ears were normal. She carries the 
c.188A>G/p.Y63C variant8. The second subject is an 8-year-old girl with a height z score of −1.7 
SD. She reached a height nadir of −3.0 SD at age 5 before the start of GH therapy for an 
indication of being small for gestational age to which she had a good response. She was 
evaluated at age 4 by a geneticist for the possibility of Russell-Silver syndrome, but no formal 
diagnosis was made. She has ptosis, epicanthal folds, downslanting eyes, and posteriorly rotated 
ears. She carries the c.925A>G/p.I309V variant9, which she inherited from her father whose 
height is 173 cm (−0.5 SD). The third subject is a 16-year-old male adolescent with a height z 
score of −2.5 SD. He reached a height nadir of −3.2 SD at age 13 before isolated GH deficiency 
was diagnosed and GH therapy was started. He also started testosterone therapy at age 15 years 
for delayed puberty. He has mild learning issues, and on examination has a low posterior hair 
line but no other facial features consistent with Noonan syndrome. He carries the 
c.853T>C/p.F285L variant9. 
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Identification of one pathological IGF1R variant among all IGF1R rare variants identified 
To demonstrate the utility of a large-scale sequencing approach and the need for careful 
interpretation of results, we focused on rare variants in IGF1R, a gene for which 
haploinsufficiency is known to cause significant short stature10–12. Our approach was to identify 
nonsynonymous variants present in case patients only that segregated with the phenotype of 
short stature within the families. Variants meeting these criteria would be classified as potentially 
pathogenic variants requiring further functional validation. In total, our targeted sequencing 
found 25 unique IGF1R variants in both case patients and control subjects. Of these, 16 were 
synonymous SNPs, most of which were common (minor allele frequency >0.01); these were not 
evaluated further. The remaining 9 variants included 6 missense, 1 frameshift, and 2 intronic 
variants. The intronic variants were found within 5 bp of an exon, which suggests a potential 
involvement in splicing, and thus were included for further analysis. Five of these variants were 
present in case patients only (Table 2.3). All 9 variants were validated via traditional Sanger 
sequencing and confirmed to be heterozygous. To determine the biological significance of these 
variants, segregation of variants 2 through 6 within families was performed (Figure 2.2). There 
was no correlation between the individual family member's heights and the carrier status of the 
variants, suggesting that these variants are not likely to be major contributors to the patients' 
short stature, and, therefore, we excluded these variants from further consideration as pathogenic 
variants. Variant 7 was present in multiple case patients and control subjects and was also not 
likely to be pathogenic. Of note, 1 of the 2 rare missense variants found only in control subjects 
in our study (variant 9) was previously reported as pathogenic in the literature13. This control 
subject is of normal stature at −0.4 SD. 
 
Table 2.3: IGF1R Potentially Nonsynonymous Variants 
 
 
Variant Exon  cDNA Protein MAF Subject Sex Height 
SD 
Birth weight, 
ga 
IGF-1 (normal 
rangeb), ng/mL 
1 2 c.418dupG p.A140Gfs*5 novel Case 1 F -4.1 unknown 389.8 (244 - 787) 
2 5 c.1247+3A>G Intron  0.0007 Case 2 F -3.9 2800  26.6 (49 - 342) 
3 7 c.1463-5C>A Intron  0.012 Case 3 M -2.4 3500  52.2 (49 - 342) 
4 6 c.1411C>T p.R471C novel  Case 4 M -2.3 4100  34 (63 - 279) 
5 7 c.1502C>T p.S501L novel Case 5 M -3.0 3400  148 (63 - 279) 
Case 6 F -2.8 2600  97.2 (49 - 342) 6 6 
  
c.1336A>G 
  
p.M446V 
  
0.0027 
  Control 6 F 0.0    
 
 
 
 
323251327 
Table 2.3 (Continued) 
Case 7a F -3.3 4200  69.9 (49 - 342) 
Case 7b F -3.1 3800  62 (63 - 279) 
Control 7a F +0.4   
Control 7b M 0.0   
7 6 
  
c.1310G>A 
  
p.R437H 
  
0.004 
  
Control 7c M -0.4   
8 5 c.1162G>A p.V388M 0.003 Control 8 M -0.6   
9 7 c.1532G>A p.R511Q 0.003 Control 9 M -0.4   
 
Abbreviations: F, female; M, male. 
 
a. All case patients were the product of full-term pregnancies (>37 weeks) with the exception of case 7b (36.5 weeks). None of the 
case patients met the definition for intrauterine growth retardation (weight <2500 g at birth for normal gestation). 
 
b. Normal range for sex and Tanner stage. All IGF-I values were obtained during a baseline clinical evaluation and were measured 
when the patient was not receiving growth hormone therapy. 
3369333137 
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Figure 2.2: Segregation of identified IGF1R nonsynonymous variants in affected 
families does not correlate with short stature. Numbers below the individuals denote 
the height z scores. ^ indicates that the height was estimated by a family member. All 
other values were measured. Individuals carrying the heterozygous variants are indicated 
as black half-filled circles (females) or squares (males). The arrow points to the affected 
proband in each family. 
 
 
 
Variant 1 was a novel frameshift mutation (c.418dupG/p.A140Gfs*5) (Figure S2.1) 
found in 1 patient in the heterozygous state. The mutation causes severe truncation of the 
protein with complete abrogation of the transmembrane and intracellular domains and 
thus was predicted to lead to haploinsufficiency. This patient was adopted from China at 
6 years of age, and therefore a complete history and familial samples could not be 
obtained. At the age of 15 years, the patient had Tanner stage 4 breast development with 
height of 136 cm (−4.06 SD), weight of 30.2 kg (−4.87 SD), and a head circumference of 
49.3 cm (−4.4 SD). She has a history notable for bilateral cleft lip and palate as well as 
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attention deficit disorder and mild developmental delay. Her IGF-I was normal at 389.8 
ng/mL (normal range, 244–787 ng/mL for a Tanner stage 4 female). GH stimulation 
testing with arginine and glucagon demonstrated a peak GH level of 18.8 ng/mL. She had 
previously been treated with GH therapy with a possible mild increase in growth velocity, 
although this occurred concurrently with entering puberty. 
Variant 1 was the only variant in IGF1R that met our prespecified criteria for 
consideration as a potential pathogenic variant. To determine whether variant 1 was 
causal for the patient's phenotype, we evaluated IGF1R expression and function in 
primary PBMCs derived from the patient compared with those in control PBMCs 
(procured from the unrelated adoptive mother). Flow cytometric analysis by FACS of 
live PBMCs (counts, y-axis; Figure 2.3) indicated that fluorescence emitted by 
IGF1R-PE-labeled PBMCs was markedly reduced (fluorescence intensity, x-axis; Figure 
2.3) in patient PMBCs compared with that by the normal control PBMCs (Figure 2.3A). 
When the live PBMCs were treated with IGF-I, emitted fluorescence was comparably 
reduced for both control and patient PBMCs, suggesting normal internalization of IGF1R 
upon ligand binding (Figure 2.3B). Immunoblot analysis of cell lysates, furthermore, 
indicated that total IGF1R expression was reduced in the patient's PBMCs with 
correlating reductions in IGF-I–induced signaling (Figure 2.3C). Taken together, the 
results are consistent with the heterozygous IGF1R c.418dupG variant inducing a state of 
IGF1R deficiency and being an excellent candidate to cause the subject's short stature. 
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
 
Figure 2.3: IGF1R expression and signaling in primary peripheral PBMCs of 
patient carrying heterozygous IGF1R c.418dupG. PBMCs were isolated as indicated 
in Materials and Methods. Flow cytometry analysis by FACS was used to detect IGF1R, 
labeled by PE-conjugated anti-human IGF1R-α antibody (see Materials and Methods), on 
the cell surface of live PBMCs. Live PBMCs (counts, y-axis) and fluorescence emitted 
by the IGF1R-PE–labeled PBMC were collated (log scale fluorescence intensity, x-axis). 
(A) Patient (red graph) compared with normal (black graph) PBMCs. Background 
fluorescence emitted by unlabeled and untreated PBMC control is shown by the 
gray-shaded region. The geometric mean of the fluorescent intensity (FI) detected in 
normal PBMCs was given an arbitrary unit of 100% (table). (B) Effect of IGF-I treatment 
(100 ng/mL, 1 hour) on the detection of IGF1R-PE–labeled PBMC from normal (top 
panel) and patient (bottom panel) PBMCs. For each, the geometric mean of the 
fluorescent intensity (FI) detected in untreated PBMCs was given an arbitrary unit of 
100%. (C) Western immunoblot analysis of total cell lysates from PBMCs treated with 
IGF-I (100 ng/mL) vs untreated cells. Molecular mass (kilodaltons) is indicated on the 
left side of the immunoblots. The intracellular proteins detected are indicated by arrows 
(on right). 
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DISCUSSION 
Short stature is a common problem confronting pediatric endocrinologists. After 
exclusion of other chronic diseases or overt hormonal deficiencies, clinicians are often 
unable to provide a definitive diagnosis for the etiology of an individual patient's short 
stature. There are a multitude of genetic causes for short stature, but most patients do not 
fall into a previously identified genetic syndrome. We, therefore, designed and performed 
a large-scale sequencing project to identify pathogenic rare genetic variants in individuals 
with short stature. We sequenced 1077 candidate genes including known skeletal 
dysplasia genes, genes within the GH signaling pathway, genes known to affect growth 
plate biology, and genes within loci associated with adult height in large GWA studies. 
Using this approach, we identified 4 known pathogenic variants causing short stature as 
well as novel variants in genes known to affect stature. 
To facilitate the sequencing of a large number of genes in many subjects, we used a 
pooled sequencing design, which significantly reduced the cost of such analysis14. Most 
of the cost associated with a targeted next-generation sequencing project is typically 
incurred at the library construction stage, in which targeted regions of DNA are separated 
from the remainder of the genome for sequencing. In a pooled sequencing design, this 
process only has to be performed once per pool. Although actual sequencing depth may 
need to be increased to ensure adequate representation of all samples in the pool, the 
associated cost is relatively minor. Indeed, the cost per sample of our pooled targeted 
sequencing approach is estimated to be ∼15% of the cost for individual exome 
sequencing (ie, ∼$110 compared with ∼$800 per sample, based on current prices 
available at our institution). Exome sequencing could also be done in a pooled fashion, in 
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which case cost differences will depend on the cost of sequencing coverage, a process 
that is becoming cheaper to perform. Although pooled exome sequencing does have the 
advantage that nearly all genes are evaluated, analysis and interpretation of the data 
generated would be much more complex because of the large number of novel 
nonsynonymous variants in genes with no known connection to the phenotype of interest. 
Our simple matrix pooling design, in contrast, allows for the rapid assessment of 
low-frequency variants in candidate genes and the identification of individuals carrying 
singleton variants, which are more likely to be pathogenic than variants with a higher 
minor allele frequency. However, pooling does limit the ability to discern whether a 
single variant is homozygous or heterozygous in an individual subject and follow-up 
confirmatory genotyping is necessary. Using this design, we were able to identify a large 
number of very rare nonsynonymous variants within our candidate genes with low false 
-positive and low false-negative rates. 
We identified 4 subjects in our cohort who had known pathogenic variants 
implicated in disease. Notably, 3 of these subjects have mutations in PTPN11 that cause 
Noonan syndrome. Noonan syndrome is known to have a wide phenotypic spectrum, 
leading to difficulty in diagnosis7, and, indeed, one of our subject's fathers carries a 
proven pathogenic variant in PTPN11 yet never presented with the overt clinical 
manifestations of Noonan syndrome. Although it is true that our subjects may have had 
features consistent with Noonan syndrome that were unrecognized, such as a cardiac 
defect or delayed puberty, this retrospective recognition of related features does not 
eliminate the benefit of genetic screening. The lack of diagnoses in our cohort represents 
clinical reality, because these subjects were extensively evaluated by experienced 
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pediatric endocrinologists and in one case by geneticist as well. This suggests that a 
substantial number of patients with Noonan syndrome are designated as having idiopathic 
short stature or isolated GH deficiency even after clinical evaluation by pediatric 
subspecialists. Additional research is needed to determine whether widespread screening 
for PTPN11 or the other Noonan syndrome genes is warranted for patients with short 
stature of unknown etiology. 
It is important to note that, in our cohort, the vast majority of HGMD-reported 
disease-causing dominant mutations did not manifest with the associated clinical 
phenotype. The classification of these variants as pathogenic is probably erroneous and 
based on insufficient clinical evidence. However, we cannot rule out the possibility that 
the variants have variable expressivity and some of our subjects are presenting on the 
very mild end of the clinical spectrum with short stature as their disease manifestation. 
Our focus on rare variants of the IGF1R gene illustrates the critical importance of 
providing supporting familial segregation and functional data when a rare variant has 
been identified. IGF-I, the primary mediator of GH function, is essential for growth. 
Heterozygous and compound heterozygous mutations in IGF1R that lead to decreases in 
the quantity or function of the receptor have been described in nearly a dozen human 
cases1,10–12,15,16. These patients display variable phenotypes, with shared characteristics 
that include poor prenatal and postnatal growth, microcephaly, high or normal IGF-I 
levels, and developmental delay1,10–12,15,16. 
Our targeted sequencing approach identified 7 unique rare 
nonsynonymous IGF1R variants as well as 2 intronic variants with the potential to affect 
splicing because of their proximity to exons. Only 1 of these 9 variants, a novel 
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c.418dupG frameshift mutation located in exon 2, was associated with clinical features 
suggestive of a pathological IGF1R deficiency state (high levels of serum IGF-1, 
microcephaly, and intrauterine growth retardation). Furthermore, in primary cells derived 
from this patient, significant decreases in both IGF1R expression and IGF-I–induced 
signaling supported the pathogenicity of the IGF1R c.418dupG defect. None of the 
remaining variants found in case patients show convincing evidence of pathogenicity. 
This example demonstrates that large-scale sequencing efforts will identify numerous 
very rare and novel nonsynonymous variants in candidate genes. Most of these variants 
will be missense variants, leading to a change in a single amino acid, which will not 
affect protein function, and represent incidental findings. Segregation of these variants 
with the phenotype within families is the first critical step in evaluating potential 
pathogenicity, highlighting the importance of collecting familial samples at the time of 
the initial DNA collection. 
Filtering strategies based on population allele frequency are useful and necessary, 
but most public databases do not provide individual phenotypic data linked to the 
subject's genotype, thus limiting the ability to determine whether a variant is potentially 
pathogenic. Therefore, simultaneous sequencing of a control cohort with a known 
phenotype, in this case normal stature, provides additional information about the lack of 
pathogenicity of rare variants in a gene. This fact is exemplified by our finding that 
an IGF1R variant previously reported to be pathogenic (c.1532G>A/p.R511Q)13 was 
found in the heterozygous state in a control subject of normal stature. This variant was 
originally identified in the heterozygous state in a patient and her maternal aunt, both of 
whom presented with extreme short stature (−6.1 and −5.7 SD, respectively). It is of note 
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that information regarding the parents of the patient were lacking in this report. In vitro 
reconstitution studies of the homozygous p.R511Q variant were performed to support the 
pathogenicity of this variant, although the effect of heterozygosity was unknown. These 
caveats, together with our identification of the same variant in a control subject of normal 
stature, strongly suggest that a heterozygous p.R511Q is not likely to be the cause of the 
previously reported family's extreme short stature. Furthermore, Kansra et al17 recently 
detected the R511Q variant in 6 of 1800 public school students. Indeed, carriers had an 
average height around the 27th percentile, thus providing additional evidence that this 
variant does not cause severe short stature. Taken together, these results support the 
importance of segregation analysis and the need to include primary cells in functional 
analysis. 
Our study has a number of important limitations. We recruited a very heterogeneous 
cohort, allowing for the inclusion of dysmorphic features, other congenital anomalies, 
and hormonal deficiencies provided that there was no known genetic etiology for these 
findings. Thus, subjects in this cohort do not meet a strict definition of idiopathic short 
stature18. Nevertheless, we believe that this cohort more accurately represents the 
diversity of patients who are seen in a referral setting and is probably enriched for 
individuals with rare genetic variants that may have multisystem effects. In addition, our 
hybrid selection strategy only targets the exons of the candidate genes, and, thus, any 
noncoding variation that affects gene expression cannot be detected by our methods. 
Variants affecting gene expression can play an important role in causing short stature. For 
example, Russell-Silver syndrome, an important syndromic form of short stature, is often 
due to abnormalities in methylation of chromosome 11p15.5, leading to aberrant gene 
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expression19. In addition, our current approach does not assess copy number variation (ie, 
deletions or duplications of genes), which may also be an important genetic defect 
leading to short stature. We are currently pursuing copy number analysis of this cohort 
using a custom chromosomal microarray (data not shown). Furthermore, we did not 
obtain perfect sequencing coverage of all variants in the targeted region and could miss 
potentially pathogenic variants in the candidate genes. Finally, because of the large 
numbers of rare missense variants in both case patients and control subjects, we have 
limited power to discover new genes with a statistically significant excess of mutations in 
case patients vs control subjects. Ongoing work to increase sample size and examine 
subjects at the extremes of the height distribution will provide additional data to support 
novel gene discovery. 
In conclusion, we present the initial results of a large-scale candidate gene 
sequencing effort in children with short stature and demonstrate the complexity of data 
interpretation of such efforts. Of our 192 subjects, 3 were found to have known 
pathogenic variants in PTPN11, highlighting the possibility that Noonan syndrome is 
underdiagnosed in the clinical setting. We report a novel frameshift mutation 
in IGF1R and demonstrate its pathogenicity in vivo. In addition, we provide evidence that 
a previously reported variant in IGF1R is not pathogenic. Analyses of variants identified 
in the other candidate genes are currently ongoing. 
 
MATERIALS AND METHODS 
Height candidate genes 
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In this study, we sequenced the exons of 1077 genes (∼2 Mb total target size). Of 
these 1077 genes, one-third (n = 356) were known biological candidates, including genes 
known to underlie syndromic growth disorders or skeletal dysplasias as well as genes 
involved in growth plate biology or GH signaling. The remaining two-thirds (n = 777) 
included genes within genomic loci associated with height based on GWA studies; 56 
genes belong to both categories (see Table S2.2)3. For the genes within the GWA loci, we 
set the genomic boundaries at each height-associated locus using linkage disequilibrium 
cutoffs (HapMap CEU r2 > 0.5) for the top single-nucleotide polymorphism (SNP). For 
loci with ≥2 genes within the genomic boundary, all genes were included. Loci with >10 
genes were excluded. For SNPs with <2 genes within the genomic boundary, genes 
beyond the boundary but within the next recombination hotspots were included. 
 
Subjects 
This study was approved by the institutional review board at Boston Children's 
Hospital (Boston, Massachusetts). All subjects or their legal guardians provided written 
informed consent. The 192 patients with short stature (>2 SD below the mean for age and 
sex)20 but without defined genetic etiologies, were recruited from the endocrinology and 
genetics clinics at Boston Children's Hospital. Because we were searching for rare 
genetic syndromes, subjects were allowed to have additional medical comorbidities, 
dysmorphic features, or other hormonal deficiencies as long as these alternate medical 
problems did not provide a clear explanation for the subject's short stature. In addition, 
192 control subjects were chosen from the Framingham Heart Study. Control subjects 
were chosen from the middle of the Framingham Heart Study height distribution (height 
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z scores between −0.7 and +0.7 SDs). z scores were calculated by regressing the height 
phenotype, stratifying by sex and adjusting for age. 
 
Sequencing protocol 
DNA samples from multiple subjects were pooled for DNA sequencing using 
previously described methods available at the Broad Institute21. To identify variants 
present only in a single individual (hereon referred to as singleton variants), we applied a 
simple overlapping pooling design (Figure S2.2). The samples from short stature subjects 
and control samples were each arranged into a 14 × 14 matrix of 28 pools, with 13 to 14 
samples in each pool. Four empty “holes” were included in each matrix for assessing the 
false-positive rate. Each sample was sequenced in 2 pools (1 row pool and 1 column 
pool). Singleton variants appear only in 1 row pool and 1 column pool. Therefore, the 
subject whose DNA sample is present at the intersection of these 2 pools must be the 
individual carrying that singleton variant. The targeted exons of the 1077 candidate genes 
were enriched using a custom Agilent SureSelect hybrid selection system. Sequencing 
was performed on the Illumina HiSeq platform. There was an average of 12961604 reads 
per pool, resulting in mean target coverage of 213 reads (15 reads per subject in a pool of 
14 subjects or 30 total reads per subject, as each subject is present in 2 pools). Variant 
calling was performed using Syzygy software21 and then a new likelihood-based 
secondary calling strategy that integrated the extra information from our matrix design 
was applied (Supplemental Methods). 
Variants were annotated for functional effect using SnpEff 2.0.5 
(http://snpeff.sourceforge.net/). Variant allele frequency data were obtained from 3 
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publicly available datasets: (1) the integrated variant call set of 1000 Genomes phase 1 
samples22 (February 2012 release); (2) the National Heart, Lung, and Blood Institute 
Exome Variant Server23, and (3) ∼12 000 sequenced genomes and exomes assembled for 
exome genotyping chip design (http://genome.sph.umich.edu/wiki/Exome_Chip_Design). 
The maximal allele frequencies from all 3 sources were used. Novel variants are those 
not observed in any of these datasets. 
 
Assessing false-positive and false-negative rates 
We estimated the false-negative and false-positive rates by comparing pooling data 
with data from exome sequencing previously performed in 6 of the short stature subjects. 
To start, we determined the overlapping targets between pooling and exome capture 
arrays. Then, limiting to sites with ≥10 reads, we assumed that the exome sequencing 
data reflected the gold standard because of its much greater depth of coverage. False 
positives were defined as singletons observed in pooling data but not in exome data, 
whereas false-negative results were those observed in exome data but not in either of the 
2 relevant pools. The false-positive rate was also estimated by looking for singleton 
variants that mapped to one of the empty holes in the matrix. The singleton variants that 
mapped to empty holes were false-positives, permitting the number of false-positive 
variants per individual to be estimated, and from there we could independently estimate 
the false-positive rate of singleton variants. 
 
IGF1R functional studies 
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Whole blood samples (BD Vacutainer Cell Preparation Tube with sodium heparin; 
Becton, Dickinson and Company, Franklin Lakes, New Jersey) were collected from the 
adopted patient and from the unrelated mother, who served as normal control subjects. 
Peripheral blood mononuclear cells (PBMCs) were isolated following the manufacturer's 
protocol. PBMCs, in freezing medium (RPMI 1640 medium + 40% fetal bovine serum + 
10% dimethyl sulfoxide) were stored in liquid nitrogen. 
For immunoblot analysis, fresh PBMCs (2 × 106/treatment) were resuspended in 
serum-free RPMI 1640 medium, with or without recombinant IGF-I (100 ng/mL; GroPep 
Ltd, Thebarton, South Australia, Australia), for 20 minutes at 37°C in a CO2 incubator, 
before pelleting, and cells were lysed as described previously for fibroblast cell cultures24. 
Western immunoblot analyses were performed as described previously24. For flow 
cytometry analysis by fluorescence-activated cell sorting (FACS) of cell surface IGF1R, 
PBMCs, warmed to 37°C from liquid nitrogen storage, were washed twice, aliquoted as 1 
× 106cells/sample in RPMI 1640 medium + 10% fetal bovine serum, and incubated 
overnight at 37°C (5% CO2 incubator). Before IGF-I treatment, cells were washed twice 
with serum-free RPMI 1640 medium + 0.5% BSA and equilibrated in 0.5 mL of 
serum-free RPMI 1640 medium for 4 hours. Cells were treated with or without IGF-I 
(100 ng/mL final concentration) for 1 hour, after which cells were washed twice with 
cold staining medium (1× PBS-0.5% BSA-0.1% sodium azide) and incubated with 
phycoerythrin (PE)–conjugated anti-human IGFIR-α (CD221; BD Biosciences, San Jose, 
California) for 30 minutes at 4°C in the dark. After antibody staining, cells were washed 
twice with cold staining medium, resuspended in 200 µL of staining medium-0.25% 
propidium iodide, and incubated on ice for 10 minutes. A total of 100 000 live PBMCs 
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(propidium iodide negative, CD221 positive) per sample were acquired via a 
FACSCaliber flow cytometer (BD Biosciences), and the fluorescence emitted by 
IGF1R-PE–labeled PBMCs was analyzed using FCS Express 3 analysis software (De 
Novo Software, Los Angeles, California). 
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NOTE ADDED AT PROOF 
After this paper was published, we were informed that PTPN11 p.I309V exists at 
7% in Ashkenazi Jews. Thus this variant is likely benign. 
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ABSTRACT 
Based on the observation of reduced stature in relatives of patients with acromesomelic 
dysplasia, type Maroteaux (AMDM), homozygous for mutations in natriuretic peptide receptor B 
gene (NPR2), it has been suggested that heterozygous mutations in this gene could be 
responsible for the growth impairment observed in some cases of idiopathic short stature (ISS), 
and some small subsequent studies provided support for this hypothesis. We enrolled 192 
unrelated patients with short stature and 7 heterozygous NPR2 missense or loss-of-function 
mutations, including one de novo splice site variant, were identified. These allelic variants were 
not found in our controls and 5 of them were not found in the public databases. NPR2 mutations 
were also found in relatives, all of whom had short stature (height SDS below -2), consistent 
with a dominant inheritance pattern. We then went on to investigate the presence of NPR2 
mutations in two larger cohorts of individuals selected from the extremes of height distribution. 
Functional studies of the NPR2 mutations identified are pending. With these functional results, 
we will be able to test more rigorously the hypothesis that NPR2 functional haploinsufficiency 
causes short stature.
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INTRODUCTION 
C-type natriuretic peptide (CNP) is a small, secreted peptide and a member of the 
natriuretic peptide family. CNP binds to a homodimeric transmembrane receptor, natriuretic 
peptide receptor B (NPR2), which functions as a guanylyl cyclase to generate cGMP in 
chondrocytes, female reproductive organs, and endothelial cells1,2. Further intracellular signaling 
occurs through cGMP-dependent protein kinases, cGMP binding phosphodiesterases, and cyclic 
nucleotide-gated ion channels.  
Several lines of evidence indicate that CNP/NPR2 signaling is an important regulator of 
skeletal growth. CNP-overexpressing mice exhibit excessive growth3, while defects of the CNP4 
or NPR25 gene, lead to impairment of skeletal development. In humans, loss-of-function 
mutations in NPR2 cause acromesomelic dysplasia, Maroteaux type (AMDM; OMIM 602875). 
This autosomal recessive skeletal dysplasia is characterized by dwarfism and short limbs6. On 
the other hand, overproduction of CNP due to a chromosomal translocation was reported to 
cause skeletal dysplasia associated with tall stature7,8. In addition, gain-of-function mutations of 
NPR2 have been identified in several studies to cause overgrowth disorder9–11.  
Interestingly, in the first report of biallelic NPR2 mutations causing AMDM, parents of 
patients with AMDM (obligate heterozygotes) were noted to be shorter than expected for their 
population of origin6, though these individuals came from a wide range of geographic and ethnic 
backgrounds, and measurements were done by a number of observers, which complicated the 
comparison. Another study that evaluated a single family with an AMDM proband showed that 
the heterozygous carriers had a mean height 1.4 SD lower than their non-carrier family 
members12. In this single-family study, the proband’s parents share a common ancestor, so it is 
possible that the heterozygous carriers share some other mutation causing short stature, and the 
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level of evidence of a heterozygous effect was limited by the size of the family. Based on these 
two studies, it is presumed that heterozygous NPR2 mutations can mildly impair long bone 
growth and it has further been hypothesized that one person in 30 with idiopathic short stature 
(ISS) will be carrier of an NPR2 mutation6,12.  
Recent studies searched for heterozygous NPR2 mutations in cohorts with ISS. One study 
of 47 independent Brazilian patients identified heterozygous NPR2 mutations in 6% of 
patients13. Another study on 101 unrelated Japanese patients with short stature identified 
heterozygous NPR2 mutations in 2% of patients14. While providing observational data consistent 
with the hypothesis that a monoallelic NPR2 mutation could cause short stature, these studies did 
not study normal height controls and were based on a relatively small number of patients, so 
have not rigorously verified the hypothesis. Analyses of larger cohorts, including controls, are 
needed to more clearly define the role of heterozygous NPR2 defects in patients with ISS.  
 
RESULTS 
Discovery of NPR2 variants in patients with short stature and controls using pooled 
sequencing 
We selected 192 patients with short stature (>2 SD below the mean for age and sex) and 
192 controls of matching ancestry from the middle of the Framingham Heart Study (FHS) height 
distribution (height z scores between -0.7 and +0.7 SDs). Characteristics of the subjects were 
described previously15. Pooled targeted sequencing of the exons of 1077 candidate genes was 
performed15. We detected 11 variants in NPR2. Of these, two were synonymous SNPs found in 
multiple patients and controls, and two were synonymous variants found only in patients. We 
focused on the seven potential loss-of-function variants, which included one splice site and 6 
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missense variants, all found in patients only (Table 3.1). These seven variants were all validated 
via traditional Sanger sequencing and confirmed to be heterozygous in each individual carrier.  
 
Family analyses and clinical phenotypes 
The splice site mutation is a C.1352-1G>A in a highly conserved base pair in the acceptor 
splice site at the 5’ end of exon 7, carried in a single patient. Sanger sequencing of the proband, 
his parents, and a brother confirmed that the variant is found in the patient but not in his mother, 
father or brother. These results were confirmed by a second round of sequencing, and paternity 
was confirmed by SNP genotyping.  There was no family history of short stature, consistent with 
the hypothesis that the de novo variant in NPR2 is contributing to short stature in this patient. 
 We also detected 6 missense variants in NPR2; of these, 4 were private variants not found 
in any of the reference databases (Patients 2-5, Table 3.1), and sequencing of relatives 
demonstrated segregation of these variants with the short stature phenotype (Figure 3.1). Of note, 
one of these variants (Patient 2) was found in a male patient who was also found to carry a 
known TRPV4 mutation (c.1858G>A, V620I) previously reported as causal for brachyolmia type 
316. The patient carries a clinical diagnosis of brachyolmia and features consistent with this 
disease, including platyspondyly of the cervical spine, and we previously reported the presence 
of this likely pathogenic variant in this patient15. The NPR2 variant was present in the patient’s 
mother, who does not carry the TRPV4 variant, and in two sisters, the elder of which also carries 
the TRPV4 variant.  The mother and both sisters had short stature with height SDS scores below -
2.5, and the sister carrying both variants had a height SDS score of -3.1. Notably patient’s father 
is deceased but also was reported to have had short stature (-3.1 SDS) and presumably carried 
the TRPV4 variant.  Thus, this patient and one of his sisters inherited the NPR2 variant from his 
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mother and the TRPV4 variant from his father, presumably resulting in severe short stature with 
skeletal dysplasia.    
We also detected two rare missense variants present in the NHLBI Exome Sequencing 
Project data base (Patients 6-7). Neither of these variants has been reported to be pathogenic, and 
both are reported to be rare (minor allele frequency 0.01%).  The mother of Patient 6, who also 
had short stature, did not carry the NPR2 variant, but DNA was not available from the sibling or 
father for further segregation analysis.  Patient 7 was adopted from China, so the family history 
of short stature was unknown and testing for segregation of the variant was not possible. 
Table 3.1: NPR2 potentially nonsynonymous variants in short stature patients 
 
Subject Sex Variant PolyPhen2 
Prediction 
Nadir Height 
SDS 
Current 
Height SDS 
GH 
Therapy 
GH 
Indication 
Upper/ 
Lower 
Patient 
1 
M Splice 
C.1352-1G>A 
N/A -3.14 -2.15 Yes ISS 1.08 
> +2 SDS 
Patient 
2 
M A48S 
(brachylomia with 
known TRPV4 variant) 
1.00 -4.15 -3.91 No N/A 1.17 
> +2 SDS 
Patient 
3 
F E389D 0.00 -3.84 -3.14 Yes ISS 0.91 
-1 SDS 
Patient 
4 
F I494S  0.997 -3.57 -1.79 Yes ISS 0.96 
0 SDS 
Patient 
5 
M A549T 0.998 -3.88 -2.70 Yes ISS  1.02 
+1-2 SDS 
Patient 
6 
M A164G 0.065 -2.53 -2.16 IGF-1 
therapy 
ISS/IGF-1 
deficiency 
1.11 
> +2 SDS 
Patient 
7 
F R787W 0.998 -2.92 -2.41 No ISS 1.06 
> +2 SDS 
Abbreviations: F, female; M, male; GH, growth hormone; IGF-1, insulin-like growth factor 1. 
 
570117 
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Figure 3.1: Segregation of identified NPR2 nonsynonymous variants in affected families. 
Numbers below the individuals denote the height z scores. + indicates family members who also 
carry the TRPV4 mutation casual of brachyolmia. ^ indicates that this family member was 
treated with growth hormone therapy prior to this height measurement and had a nadir height of -
2.8 SDS. * indicates that the height was estimated by a family member. All other values were 
measured. Individuals with short stature are indicated as black circles (females) or squares 
(males). The arrow points to the affected proband in each family.  
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Screening for NPR2 mutations in cohorts of height extreme individuals 
We then went on to screen for NPR2 mutations in two additional cohorts. The first cohort 
of individuals (n=272) was selected from the extremes (<1st percentile or >99th percentile) of 
height distribution from four FINRISK surveys (~33,000 samples in total). Pooled targeted 
sequencing of the exons of 1077 candidate genes was performed. We detected 8 potential 
variants in NPR2. Of these variants, two were common synonymous SNPs (observed in the short 
stature patients and FHS controls as well) and one was an intronic variant found in both short 
and tall extremes, and we did not pursue these further. Among the remaining 5 missense variants, 
2 were validated by Sequenom genotyping and confirmed to be heterozygous in tall extremes 
only (Table 3.2). One of these is located in the extracellular region at the ligand binding domain 
(p.N247D) and the other is located at the kinase homology domain (p.R562Q). Neither variants 
were found in any of the reference databases. An in silico analysis suggested that one mutation is 
benign (p.N247D) and the other is probably damaging (p.R562Q). 
The second cohort of individuals (n=1,000) was extremes (<1.25th percentile or >98.75th 
percentile) of height distribution from Estonian Biobank (~52,000 samples in total). Pooled 
targeted sequencing of the exons of four candidate genes was performed. Again, we did not 
evaluate further the synonymous or intronic variants identified. There were two missense variant 
observed in both tall extreme and short extreme samples, which we did not pursue further either. 
For the remaining 6 missense variants, we performed Sanger sequencing and validated 3 
singleton variants (Table 3.2) all found in short extremes only.  Two of them are located in the 
extracellular region at the ligand binding domain (p.E76K, p.G39R). The third mutation is 
located at the kinase homology domain (p.T661K). These allelic variants were not found in any 
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of the reference databases. An in silico analysis suggested that the three missense mutations are 
possibly damaging (p.E76K), benign (p.G39R), and probably damaging (p.T661K) respectively. 
 
Table 3.2: NPR2 potentially nonsynonymous variants in FINRISK and Estonian GeneBank 
height extreme samples 
 
Variant Observation PolyPhen2 Prediction 
p.N247D FINRISK tall extreme 0.002 
p.R562Q FINRISK tall extreme 0.995 
p.E76K Estonian short extreme 0.609 
p.G39R Estonian short extreme 0.013 
p.T661K Estonian short extreme 0.999 
 
Overall observation of NPR2 mutations across three cohorts 
Overall, across three cohorts, we observed 12 NPR2 nonsynonymous variants, 10 in short 
stature samples, and 2 in tall extreme samples (Table 3.3). Assuming that all variants are equally 
likely to occur in short stature samples and tall extreme samples (or control samples of normal 
height) under the null hypothesis, our observation gives a p value of 0.018 (one-tailed test).  
We hypothesize that the 2 missense variants observed in FINRISK tall extremes are 
either functional neutral or gain-of-function mutations, while the missense variants identified in 
Estonian short extremes and in the seven short stature cases are loss-of-function mutations. If the 
hypothesis is validated, the association signal will be stronger than described above, as 
functional neutral variants can be removed from the test. 
 
Table 3.3: Observation of NPR2 nonsynonymous variants in three cohorts 
Cohort Observation of  
nonsynonymous variants  
Note 
Short stature patients  
and FHS controls 
7 variants in 192 short stature patients 
0 variant in 192 FHS controls 
Patient 1: de novo mutation 
Patients 2-6: all heterozygous relatives 
had short stature (height SDS < -2) 
Patient 7: no family data available 
Extremes of FINRISK  
height distribution 
0 variant in 136 short extremes 
2 variants in 136 tall extremes 
No family data available 
Extremes of Estonian Biobank  
height distribution 
3 variants in 500 short extremes  
0 variant in 500 tall extremes 
No family data available 
 
61417 
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Functional characterization of NPR2 variants 
To further examine the pathogenicity of the identifed NPR2 nonysnonymous variants 
(Table 3.3), we initiated experiments assessing the CNP-dependent cGMP-producing capacities, 
and results are still pending. It will be interesting to see whether the results of functional studies 
are consistent with the outcome of familial analyses. We also intend to evaluate the correlation 
between in silico prediction of mutation effects with the results of functional studies. 
 
Discussion
In summary, to explore the role of NPR2 variation in short stature, we have screened for 
heterozygous NPR2 mutations in three different cohorts (Table 3.3). Familial analyses in the 
short stature patient cohort support the hypothesis that rare heterozygous NPR2 variants could be 
a major contributor short stature in individuals carrying these variants. Functional studies of the 
NPR2 mutations identified are pending, which could add further support for this hypothesis. We 
also identified NPR2 mutations in two additional cohorts, where family data are not available. 
Pending results of functional studies will be crucial in interpreting these discoveries, especially 
as we identified two variants in individuals from the tall extreme of the height distribution. The 
frequencies of heterozygous mutation carriers in varied across cohorts. This is likely due to 
different ethnicities, sample selection criteria, and possibly experimental design.  
In contrast with homozygous mutations in NPR2, which produces a severe short stature 
and body disproportion, heterozygous mutations in NPR2 seem to be associated with mild and 
variable growth impairment without distinct phenotype. The severity of short stature, body 
proportions, and the presence of nonspecific skeletal abnormalities vary across individuals in our 
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study, consistent with previous observations12,13. This variability is likely due to differences in 
the nature of NPR2 mutations carried by the individuals, as well as variable expressivity. 
Previously, a study of 47 Brazilian patients identified heterozygous NPR2 mutations in 
6% of patients13, while another study on 101 short stature Japanese patients identified mutations 
in 2% of patients14. Functional analyses were performed in both studies to evaluate the 
pathogenicity and elucidate the molecular mechanisms of the identified mutations. However, 
both studies were observations based on small number of patients. Our study, in much larger 
cohorts and with more family data, with functional analyses (once completed), will be a more 
rigorous assessment of heterozygous mutations in NPR2 as a potential cause of growth 
impairment in ISS patients. 
The frequency of heterozygous carriers of AMDM mutations was previously estimated to 
be ~0.14%12. In NHLBI, the cumulative frequency of all nonsynonymous NPR2 variants is 
approximately 0.4% in ~4000 European American samples. The discrepancy between these two 
allele frequencies highlights the importance of functional studies, which boost the power of rare 
variant association tests by removing neutral background variants. Despite the rarity of AMDM 
mutations (and nonsynonymous NPR2 variants in general), these loss-of-function alleles likely 
have relatively large effect size (previously estimated to be around -1.8 SDS12) and would 
explain ~1% of height variation in the population based on these assumptions. Moreover, 
common variants at the locus and in this pathway also contribute to height variation, as GWAS 
signals have been identified near both NPR2 and NPPC, encoding the ligand CNP.  
The action of natriuretic peptide system on longitudinal growth is partially explained by 
the capacity of CNP/NPR2 signaling to inhibit fibroblast growth factor receptor-3 (FGFR3) 
downstream signaling at the level of the MAPK cascade17. Gain-of-function mutations in 
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FGFR3, which promote a sustained activation of the MAPK pathway, are responsible for 
achondroplasia, one of the most common skeletal dysplasia18. It has been shown that CNP 
alleviates the short-limbed phenotype of achondroplasia mice19. The CNP analog with an 
extended half-life, BMN 111, has recently been developed and significantly recovery of bone 
growth was demonstrated in ACH mice by subcutaneous administration of BMN 11120.  
While this therapeutic approach would be ineffective in AMDM patients that lack the 
receptor for CNP, this form of therapy might be effective for heterozygous carriers of NPR2 
mutations who still have one functional receptor. A study by Olney et al. has shown that plasma 
CNP level was very high in AMDM patients, suggesting the presence of a feedback loop that 
regulates CNP production12. For the heterozygous carriers of the mutation, this level was not 
different from the noncarriers. In the normal population, blood level of CNP is lower in adults 
than in children. It is therefore also possible that NPR2 mutation carriers have abnormal level of 
CNP during childhood but normal level in adulthood. This finding would likely not have been 
detected in the study of Olney et al. because most of the participants were adults. 
Apart from CNP, it is conceivable that pharmacological inhibitors of the MEK/ERK 
MAPK pathway might improve bone growth for AMDM patients and heterozygous carriers. 
MEK1/2 inhibitors that are currently undergoing clinical evaluation in cancer are promising 
therapeutic candidates for growth defects associated with excess MEK1/2 signaling, including 
patients with AMDM, achondroplasia or other appropriate skeletal dysplasia. It has been shown 
that pharmacological inhibition of MEK1/2 is sufficient to rescue the growth defect in mice 
model of AMDM21. The key to moving skeletal dysplasia therapeutics forward will be to deliver 
this class of agents specifically to the growth plate. 
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AMDM patients appear to have an abnormality in the GH/IGF-1 system, characterized by 
low insulin-like growth factor 1 (IGF-1) levels, high growth hormone (GH) levels, and lack of a 
response to GH treatment12. This implies an interaction between CNP/NPR2 and GH/IGF-1 
pathways during postnatal growth and the growth failure in AMDM may be due at least partially 
to low IGF-1 levels. Studies in more children with AMDM will test this hypothesis. IGF-1 
levels, however, were not low in the carriers12–14. It is possible, as mentioned earlier, that carriers 
have abnormal levels of IGF-1 during childhood that were not detected. Studies that will advance 
our knowledge of these mechanisms can eventually help predict the determinants for 
responsiveness to therapy. This knowledge would allow clinicians to tailor GH treatment and 
dosing to an individual’s molecular diagnosis. It may be useful in the future to include NPR2 
sequencing in the evaluation of children presenting with short stature. This information could 
then be used to help make the decision of whether to start growth hormone. 
 
MATERIALS AND METHODS 
Subjects 
Short stature patient cohort 
192 patients with short stature (>2 SD below the mean for age and sex22) but without 
defined genetic etiologies, were recruited from the endocrinology and genetics clinics at Boston 
Children's Hospital. In addition, 192 control subjects were chosen from the middle of the 
Framingham Heart Study height distribution (height z scores between −0.7 and +0.7 SDs). More 
detailed description of the cohort is reported in Wang et al.15  
 
FINRISK height extreme cohort 
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272 subjects were chosen from the extremes (<1st percentile or >99th percentile) of the 
FINRISK surveys (FINRISK 1992, FINRISK 1997, FINRISK 2002, FINRISK 2007) height 
distribution. The FINRISK cohorts comprise the respondents of representative, cross-sectional 
population surveys that are carried out every 5 years since 1972, to assess the risk factors of 
chronic diseases and health behavior in the working age population, in five large study areas of 
Finland23. 
 
Estonian Biobank height extreme cohort 
1000 subjects were selected from the extremes (<1.25th percentile or >98.75th percentile) 
of the Estonian Biobank height distribution. The Estonian Biobank cohort is a volunteer-based 
sample of the Estonian resident adult population (age ≥18 years). The age, sex and geographical 
distribution closely reflect those of the Estonian adult population and encompass close to 5% of 
the entire adult population of Estonia24. 
 
Pooled sequencing protocol 
DNA samples from multiple subjects were pooled for DNA sequencing using previously 
described methods available at the Broad Institute25. To identify variants present only in a single 
individual (hereon referred to as singleton variants), we applied a simple overlapping pooling 
design as described in Wang et al.15. In short, each sample was sequenced in 2 pools (1 row pool 
and 1 column pool). Singleton variants appear only in 1 row pool and 1 column pool. Therefore, 
the subject whose DNA sample is present at the intersection of these 2 pools must be the 
individual carrying that singleton variant. 
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Sequencing was performed on the Illumina HiSeq platform. Variant calling was performed 
as described previously15. Variants were annotated for functional effect using SnpEff 2.0.5 
(http://snpeff.sourceforge.net/). Variant allele frequency data were obtained from the National 
Heart, Lung, and Blood Institute Exome Variant Server26. 
Confirmation of variants found in NPR2 through pooled sequencing was done via Sanger 
sequencing or Sequenom genotyping. Each variant was sequenced in the proband and in all 
related family members for whom DNA samples were provided.   
 
Short stature patient cohort 
The samples from short stature subjects and control samples were each arranged into a 14 
× 14 matrix of 28 pools, with 13 to 14 samples in each pool. The coding regions of NPR2 were 
sequenced along with ~1000 height candidate genes15. The targeted exons of the candidate genes 
were enriched using a custom Agilent SureSelect hybrid selection system. The mean target 
coverage of NPR2 is 297 reads per pool, resulting in 21 reads per subject in a pool of 14 subjects 
or 42 total reads per subject, as each subject is present in 2 pools. 
 
FINRISK height extreme cohort 
The FINRISK DNA samples were whole-genome amplified. The short extreme subjects 
and the tall extreme subjects were each arranged into a 12 × 12 matrix of 24 pools, with 11-12 
samples in each pool. The coding region of NPR2 was enriched as described above for short 
stature patient cohort. The mean target coverage of NPR2 is 377 reads per pool, resulting in 31 
reads per subject in a pool of 12 subjects or 62 total reads per subject. 
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Estonian Biobank height extreme cohort 
The samples from short extreme subjects and tall extreme subjects were each arranged 
into a 24 × 24 matrix of 48 pools, with 19-24 samples in each pool. The coding regions of NPR2 
were sequenced along with three other genes. The targeted exons of all four genes were enriched 
using PCR-based fluidigm Access Array system. The mean target coverage of NPR2 is 2735 
reads per pool, resulting in 114 reads per subject in a pool of 24 subjects or 228 total reads per 
subject. 
 
In silico prediction of mutation effects 
To identify the potential effects of sequence variants identified in NPR2 on protein 
function or structure, the wild-type and variant sequences were submitted to the PolyPhen 
method (http://genetics.bwh.harvard.edu/pph2)27. 

Assaying wild-type and mutant NPR2 activity 
Missense mutations in NPR2 will be generated by site-directed mutagenesis using the 
wild-type rat NPR2 expression construct pRK-NPR-B. Activity in HEK 293 cells will be 
measured as described elsewhere28. In brief, cells will be seeded to 40%-45% confluency in 10-
cm dishes in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). 
The cells will be transfected 2 d later with 4 µg of expression construct with Lipofectamine 
(Invitrogen) in serum-free DMEM. After transfection, cells will be supplemented with 15% FBS 
and incubated overnight. Transfection efficiency is expected to be 40-50%, as determined by 
cotransfecting cells with a green fluorescent protein reporter plasmid. Transfected cells will be 
starved for 12 h prior to CNP exposure (48-72 h after transfection). Cells will then be exposed to 
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1µM CNP (Bachem) for 3 min. Signaling will be terminated by aspirating the CNP-containing 
media and adding ice-cold 80% ethanol to the cells. This ethanol extract will be centrifudged, 
and the supernatant will be collected and vacuum evaporated. The amount of cGMP in the 
evaporated samples will be measured by use of a cGMP assay kit (Cayman Chemical). 
 
References 
1. Schulz, S. (2005). C-type natriuretic peptide and guanylyl cyclase B receptor. Peptides 26, 
1024–1034. 
 
2. Potter, L.R., Abbey-Hosch, S., and Dickey, D.M. (2006). Natriuretic peptides, their receptors, 
and cyclic guanosine monophosphate-dependent signaling functions. Endocr. Rev. 27, 47–72. 
 
3. Yasoda, A., Komatsu, Y., Chusho, H., Miyazawa, T., Ozasa, A., Miura, M., Kurihara, T., 
Rogi, T., Tanaka, S., Suda, M., et al. (2004). Overexpression of CNP in chondrocytes rescues 
achondroplasia through a MAPK-dependent pathway. Nat. Med. 10, 80–86. 
 
4. Chusho, H., Tamura, N., Ogawa, Y., Yasoda, A., Suda, M., Miyazawa, T., Nakamura, K., 
Nakao, K., Kurihara, T., Komatsu, Y., et al. (2001). Dwarfism and early death in mice lacking C-
type natriuretic peptide. Proc. Natl. Acad. Sci. U. S. A. 98, 4016–4021. 
 
5. Tamura, N., Doolittle, L.K., Hammer, R.E., Shelton, J.M., Richardson, J.A., and Garbers, D.L. 
(2004). Critical roles of the guanylyl cyclase B receptor in endochondral ossification and 
development of female reproductive organs. Proc. Natl. Acad. Sci. U. S. A. 101, 17300–17305. 
 
6. Bartels, C.F., Bükülmez, H., Padayatti, P., Rhee, D.K., van Ravenswaaij-Arts, C., Pauli, R.M., 
Mundlos, S., Chitayat, D., Shih, L.-Y., Al-Gazali, L.I., et al. (2004). Mutations in the 
transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause 
acromesomelic dysplasia, type Maroteaux. Am. J. Hum. Genet. 75, 27–34. 
 
7. Moncla, A., Missirian, C., Cacciagli, P., Balzamo, E., Legeai-Mallet, L., Jouve, J.-L., Chabrol, 
B., Le Merrer, M., Plessis, G., Villard, L., et al. (2007). A cluster of translocation breakpoints in 
2q37 is associated with overexpression of NPPC in patients with a similar overgrowth 
phenotype. Hum. Mutat. 28, 1183–1188. 
 
8. Bocciardi, R., Giorda, R., Buttgereit, J., Gimelli, S., Divizia, M.T., Beri, S., Garofalo, S., 
Tavella, S., Lerone, M., Zuffardi, O., et al. (2007). Overexpression of the C-type natriuretic 
peptide (CNP) is associated with overgrowth and bone anomalies in an individual with balanced 
t(2;7) translocation. Hum. Mutat. 28, 724–731. 
 
 70 
9. Miura, K., Kim, O.-H., Lee, H.R., Namba, N., Michigami, T., Yoo, W.J., Choi, I.H., Ozono, 
K., and Cho, T.-J. (2014). Overgrowth syndrome associated with a gain-of-function mutation of 
the natriuretic peptide receptor 2 (NPR2) gene. Am. J. Med. Genet. A 164A, 156–163. 
 
10. Robinson, J.W., Dickey, D.M., Miura, K., Michigami, T., Ozono, K., and Potter, L.R. (2013). 
A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of 
guanylyl cyclase-B. Bone 56, 375–382. 
 
11. Miura, K., Namba, N., Fujiwara, M., Ohata, Y., Ishida, H., Kitaoka, T., Kubota, T., Hirai, H., 
Higuchi, C., Tsumaki, N., et al. (2012). An overgrowth disorder associated with excessive 
production of cGMP due to a gain-of-function mutation of the natriuretic peptide receptor 2 
gene. PLoS One 7, e42180. 
 
12. Olney, R.C., Bükülmez, H., Bartels, C.F., Prickett, T.C.R., Espiner, E.A., Potter, L.R., and 
Warman, M.L. (2006). Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are 
associated with short stature. J. Clin. Endocrinol. Metab. 91, 1229–1232. 
 
13. Vasques, G.A., Amano, N., Docko, A.J., Funari, M.F.A., Quedas, E.P.S., Nishi, M.Y., 
Arnhold, I.J.P., Hasegawa, T., and Jorge, A.A.L. (2013). Heterozygous Mutations in Natriuretic 
Peptide Receptor-B (NPR2) Gene as a Cause of Short Stature in Patients Initially Classified as 
Idiopathic Short Stature. J. Clin. Endocrinol. Metab. 98, E1636–E1644. 
 
14. Amano, N., Mukai, T., Ito, Y., Narumi, S., Tanaka, T., Yokoya, S., Ogata, T., and Hasegawa, 
T. (2014). Identification and Functional Characterization of Two Novel NPR2 Mutations in 
Japanese Patients with Short Stature. J. Clin. Endocrinol. Metab. jc20133525. 
 
15. Wang, S.R., Carmichael, H., Andrew, S.F., Miller, T.C., Moon, J.E., Derr, M.A., Hwa, V., 
Hirschhorn, J.N., and Dauber, A. (2013). Large Scale Pooled Next-Generation Sequencing of 
1077 Genes To Identify Genetic Causes of Short Stature. J. Clin. Endocrinol. Metab. 
 
16. Rock, M.J., Prenen, J., Funari, V.A., Funari, T.L., Merriman, B., Nelson, S.F., Lachman, 
R.S., Wilcox, W.R., Reyno, S., Quadrelli, R., et al. (2008). Gain-of-function mutations in 
TRPV4 cause autosomal dominant brachyolmia. Nat. Genet. 40, 999–1003. 
 
17. Krejci, P., Masri, B., Fontaine, V., Mekikian, P.B., Weis, M., Prats, H., and Wilcox, W.R. 
(2005). Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of 
chondrocyte proliferation and extracellular matrix homeostasis. J. Cell Sci. 118, 5089–5100. 
 
18. Vajo, Z., Francomano, C.A., and Wilkin, D.J. (2000). The molecular and genetic basis of 
fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, 
Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev. 21, 
23–39. 
 
19. Yasoda, A., Kitamura, H., Fujii, T., Kondo, E., Murao, N., Miura, M., Kanamoto, N., 
Komatsu, Y., Arai, H., and Nakao, K. (2009). Systemic administration of C-type natriuretic 
peptide as a novel therapeutic strategy for skeletal dysplasias. Endocrinology 150, 3138–3144. 
 71 
 
20. Lorget, F., Kaci, N., Peng, J., Benoist-Lasselin, C., Mugniery, E., Oppeneer, T., Wendt, D.J., 
Bell, S.M., Bullens, S., Bunting, S., et al. (2012). Evaluation of the therapeutic potential of a 
CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am. J. Hum. Genet. 91, 
1108–1114. 
 
21. Geister, K.A., Brinkmeier, M.L., Hsieh, M., Faust, S.M., Karolyi, I.J., Perosky, J.E., Kozloff, 
K.M., Conti, M., and Camper, S.A. (2013). A novel loss-of-function mutation in Npr2 clarifies 
primary role in female reproduction and reveals a potential therapy for acromesomelic dysplasia, 
Maroteaux type. Hum. Mol. Genet. 22, 345–357. 
 
22. Kuczmarski, R.J., Ogden, C.L., Guo, S.S., Grummer-Strawn, L.M., Flegal, K.M., Mei, Z., 
Wei, R., Curtin, L.R., Roche, A.F., and Johnson, C.L. (2002). 2000 CDC Growth Charts for the 
United States: methods and development. Vital Health Stat. 11. 1–190. 
 
23. Vartiainen, E., Laatikainen, T., Peltonen, M., Juolevi, A., Männistö, S., Sundvall, J., 
Jousilahti, P., Salomaa, V., Valsta, L., and Puska, P. (2010). Thirty-five-year trends in 
cardiovascular risk factors in Finland. Int. J. Epidemiol. 39, 504–518. 
 
24. Leitsalu, L., Haller, T., Esko, T., Tammesoo, M.-L., Alavere, H., Snieder, H., Perola, M., Ng, 
P.C., Mägi, R., Milani, L., et al. (2014). Cohort Profile: Estonian Biobank of the Estonian 
Genome Center, University of Tartu. Int. J. Epidemiol. 
 
25. Rivas, M.A., Beaudoin, M., Gardet, A., Stevens, C., Sharma, Y., Zhang, C.K., Boucher, G., 
Ripke, S., Ellinghaus, D., Burtt, N., et al. (2011). Deep resequencing of GWAS loci identifies 
independent rare variants associated with inflammatory bowel disease. Nat. Genet. 43, 1066–
1073. 
 
26. National Heart, Lung, and B.I. Exome Variant Server. 
 
27. Ramensky, V., Bork, P., and Sunyaev, S. (2002). Human non-synonymous SNPs: server and 
survey. Nucleic Acids Res. 30, 3894–3900. 
 
28. Abbey, S.E., and Potter, L.R. (2003). Lysophosphatidic acid inhibits C-type natriuretic 
peptide activation of guanylyl cyclase-B. Endocrinology 144, 240–246.  
 
 
 
 
Chapter 4 
 
Simulation of Finnish population history, guided by empirical 
genetic data, to assess power of rare variant tests in Finland 
 
 
Sophie R. Wang1,2,3, Vineeta Agarwala2,4,5, Jason Flannick2,6, Charleston W.K. Chiang7, David 
Altshuler2,3,6,8, GoT2D Consortium, Joel N. Hirschhorn1,2,3, 
 
1. Division of Endocrinology, Boston Children’s Hospital, Boston, MA 02115, USA 
2. Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, 
USA 
3. Department of Genetics, Harvard Medical School, Boston, MA 02115, USA 
4. Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of 
Technology, Cambridge, MA 02139, USA 
5. Program in Biophysics, Graduate School of Arts and Sciences, Harvard University, 
Cambridge, MA 02138, USA 
6. Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, 
USA 
7. Department of Ecology and Evolutionary Biology, University of California, Los Angeles, 
CA 90095, USA 
8. Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, 
USA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Originally published as: 
Wang SR, et al. Simulation of Finnish population history, guided by empirical genetic data, to 
assess power of rare-variant tests in Finland. Am J Hum Genet, 2014. 94(5): p.710-20.
 73 
ABSTRACT 
Finnish samples have been extensively utilized in studying single-gene disorders, where 
the founder effect has clearly aided in discovery, and more recently in genome-wide association 
studies (GWAS) of complex traits, where the founder effect has had less obvious impacts. As the 
field starts to explore rare variants’ contribution to polygenic traits, it is of great importance to 
characterize and confirm the Finnish founder effect in sequencing data and to assess its 
implications for rare variants association studies. Here, we employ forward simulation, guided 
by empirical deep resequencing data, to model the genetic architecture of quantitative polygenic 
traits in both the general European and the Finnish population simultaneously. We demonstrate 
that power for rare variant association tests is higher in the Finnish population, especially when 
variants’ phenotypic effects are tightly coupled with fitness effects and therefore reflect a greater 
contribution of rarer variants. SKAT-O, VT, and single variant tests are more powerful than 
other rare variant methods in the Finnish population across a range of genetic models. We also 
compare the relative power and efficiency of exome array genotyping vs. high coverage exome 
sequencing. At a fixed cost, less expensive genotyping strategies have far greater power than 
sequencing; in a fixed number of samples, however, genotyping arrays miss a substantial portion 
of genetic signals detected in sequencing, even in the Finnish founder population. As genetic 
studies probe sequence variation at greater depth in more diverse populations, our simulation 
approach provides a framework to evaluate various study designs for gene discovery. 
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INTRODUCTION 
A founder effect can result either from a true founder event (i.e., the establishment of a new 
population from a limited pool of individuals) or from an extreme reduction in population size 
(i.e., a bottleneck in size), followed by relative genetic isolation from other populations. The 
population of Finland is one of the best-studied genetic isolates. The Finnish genetic architecture 
has been shaped by a series of founder effects and a subsequent drift in local subisolates. The 
initial founder effects are generally associated with two colonization waves 4000 and 2000 years 
ago to southern and western Finland. More recently, there was an internal migration movement 
in the 15th-16th century from a small southeastern area to the middle, western and finally 
northern and eastern parts of the country1. 
The Finnish population has been extensively utilized in genetic studies. It is considered to be 
a relatively homogenous large founder population, and hence potentially well suited for genetic 
mapping. The evidence for a founder effect includes enrichment of almost forty rare recessive 
diseases, longer regions of linkage disequilibrium, increased kinship coefficients between pairs 
of randomly chosen individuals, and extended runs of homozygosity1–10. In part because of the 
founder effect, identification of the genes underlying the rare diseases enriched in Finland has 
been remarkably successful.1 Finnish samples have also contributed to many GWAS of complex 
traits, but because common (>5% minor allele frequency, MAF) variation is less influenced by 
human population history, a founder effect would be less likely to provide a specific advantage 
in this setting. 
Studies of polygenic traits and disorders are now moving to a middle ground between GWAS 
genotyping methods (thus far focused largely on common variation, typically MAF >5%) and 
sequencing-based methods that were most successfully employed to identify extremely rare 
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variants in single gene disorders. This middle ground is association studies of lower frequency 
variants (MAF <5%), analyzed either individually or in aggregate (the aggregate analysis has 
also been termed RVAS11). As such, it is of great interest and importance to confirm the Finnish 
founder effect in sequencing data that includes rarer variants and assess the implications for these 
association studies of rarer variants. Due to the founding event and subsequent strong genetic 
drift, some variants that are rare in the ancestral population will have risen in frequency in a 
founder population, while others will have decreased or disappeared. These alterations in allele 
frequency could potentially increase power of rare variant tests in two ways. First, some rare and 
potentially deleterious variants could rise to higher frequencies, out of proportion to what might 
be expected given their deleterious effects.  Second, there is greater homogeneity of rare 
variation in a founder population, and thus fewer background rare variants at any individual 
locus.  As an example, a protective mutation for Alzheimer’s disease (MIM 104300) was 
discovered in part because it has a much higher frequency in the Scandinavian populations 
(~0.4%) than in the general European population (<0.01%)12. 
Exome sequencing studies are emerging as a popular approach to identify rare coding 
variants associated with complex traits, while a cheaper alternative approach is to use array-
based genotyping of a defined set of coding variants. The human genetics community has 
aggregated an extensive list of putative functional coding variants from the exome sequences of 
>12,000 individuals for array-based genotyping platforms (e.g. the Illumina Infinium 
HumanExome BeadChip and the Affymetrix Axiom Exome Array Plate; see URL for a 
description of SNP content and selection strategies). Although these arrays do not provide a 
complete catalogue of all coding variants, the set of variants selected for array design is 
estimated to include >97% of the non-synonymous variants that would be detected in any 
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individual genome through exome sequencing.  In theory, the coverage would be even higher for 
a founder population, which has fewer rare variants compared to a non-founder population. 
To increase power to detect effects of rare variants, especially those that are too infrequent to 
be individually tested for association, many groups have devised tests that combine evidence 
across multiple variants13. These tests have become a standard approach for analyzing rare 
variants, and include burden tests14–16 and other types of tests that aggregate evidence across sets 
of variants17,18. The relative power of such tests to detect association is strongly influenced by 
underlying genetic architecture.  Specifically, the proportion of causal variants among all 
variants analyzed and the distribution of effect sizes and allele frequencies of causal variants all 
affect test performance. Different statistical tests also have different sets of parameters, the 
values of which can have a large effect on the power of the tests. 
Different diseases and phenotypes likely have different architectures19. To try to evaluate 
how different sample selections (founder vs. non-founder populations), analytical methods 
(single variant tests, gene-based tests), and study designs (exome sequencing vs. exome array 
genotyping) would perform with different genetic architectures, we have developed a population 
genetics framework to assess the impact of the Finnish population history on genetic studies of 
rarer variation. Our approach has four basic stages: 1) confirming and characterizing the Finnish 
founder effect in sequence data, 2) developing a simultaneous simulation of sequence variation 
in the non-Finnish European (NFE) population and the Finnish population that closely 
approximates the sequence data, 3) specifying a range of models of genetic architectures to 
generate simulated phenotypic data, and 4) comparing operating characteristics of different gene-
based tests and single variant tests on phenotype, genotype, and sequence data from simulated 
founder and non-founder populations.  
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With this framework in place, we address the following questions: 1) Under what types of 
genetic architecture(s) is it more powerful to use a founder population such as Finland? 2) Under 
different genetic models, what are the optimal association tests for rare variants in a founder 
population? 3) How does power compare between using exome sequencing data and exome chip 
data, particularly in a founder population? Our results show that power to detect genetic signals – 
by both single variant and gene-based tests – is higher in samples from the Finnish founder 
population than in equivalently sized NFE samples, especially when the phenotypic effects of 
variants are tightly coupled with effects on fitness. SKAT-O, VT, and single variant tests have 
the highest mean power in a founder population across simulated datasets. At a fixed cost, 
genotyping strategies have far greater power than sequencing; in a fixed number of samples, 
however, genotyping arrays miss a substantial portion of causal variation detected in sequencing.   
 
RESULTS 
 
Assessing the Finnish founder effect 
We analyzed whole exome sequence data of NFE and Finnish samples from the GoT2D 
Project (see Methods). If the Finnish population had been through a founding event in the past, 
there are a number of direct predictions for the allele frequency spectra (AFS) and the sharing of 
variants between the Finns and the NFEs. We showed that, when comparing Finnish and NFE 
samples of the same size (N=500), the allele frequency spectra (AFS) are shifted towards higher 
frequencies in the Finns (Figure 4.1).  The proportion of singleton variants is much lower in the 
Finns than the NFEs (28% vs. 46% for synonymous variants, 39% vs. 57% for missense 
variants), while the opposite is true for common variants (>5%) (31% vs. 22% for synonymous 
variants, 19% vs. 12% for missense variants). Furthermore, singleton variants in a population of 
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Finns (N=250) are more likely to be seen again in another population of Finns (N=250), 
compared with the same analysis in NFEs (34% vs. 23% for synonymous singleton variants, 30% 
vs. 20% for missense singleton variants) (Figure S4.1). We also observed that SNPs found in 
both samples tend to have higher frequencies in Finns (paired t-test p value < 0.01) (Table S4.1). 
Compared to the NFEs, the Finns have lower level of heterozygosity (on average there are 0.6% 
fewer heterozygous sites per individual in the Finns, t-test p value < 0.01) and reduced genetic 
diversity (Watterson’s estimate adjusted by sequence length is 6.14×10-4 for the Finns and 
1.01×10-3 for the NFEs). All these results strongly confirm the presence of a founder effect in 
Finland. 
 79 
 
Figure 4.1: The final demographic model for simulating NFEs and Finns simultaneously. 
The NFEs were modeled as long-term (45,000 generations) constant size (N=8,100) followed by 
a bottleneck (N=2,000) and then by exponential growth (1.5% growth per generation). For 
modeling the Finns, we tested three general classes of models, of which only one (Class 3 in 
Tables S2) approximated the empirical observations.  In this model, after the initial founding 
event (100 generations ago, N=1,000), the Finn-s went through a slow growth phase (0.5-5% 
growth per generation), and then a more recent fast growth phase (8-30% growth per 
generation); there was gene flow from the NFEs to the Finns. 
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Simulation of coding sequence variation in hundreds of thousands of samples 
To enable a controlled characterization of the performance of different sample selections, 
analytical methods and study designs under a range of scenarios, we used the forward simulation 
package ForSim20 to generate coding sequence data for the NFEs and the Finns simultaneously. 
This way, we could simulate evolution of complex traits over time in large samples and we know 
the truth (i.e. fitness effects) about all variants. To model the NFEs, we used the conventional 
four-parameter model21 and adapted parameters from a recent simulation that generated 
representative sequence data for European populations (Figure 4.2)22. We further modeled the 
Finns as a founder population established by a small number of NFEs. We refined our 
demographic parameters for the Finnish model by comparing to exome sequencing data from the 
GoT2D project (see Method).   In our final model, the initial founding event was followed by a 
slow growth phase, and then a more recent fast growth phase, with gene flow from the NFEs to 
Finns (Figure 4.2). Figure 4.3 shows that our final demographic model reproduces the observed 
allele frequency spectra well. We also analyzed missense/synonymous ratio (Figure S4.2) and 
allele sharing between the Finns and the NFEs (Figure S4.3); these metrics are also similar 
between the observed and simulated data.  
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Figure 4.2: The final demographic model for simulating NFEs and Finns simultaneously. 
The NFEs were modeled as long-term (45,000 generations) constant size (N=8,100) followed by 
a bottleneck (N=2,000) and then by exponential growth (1.5% growth per generation). For 
modeling the Finns, we tested three general classes of models, of which only one (Class 3 in 
Tables S2) approximated the empirical observations.  In this model, after the initial founding 
event (100 generations ago, N=1,000), the Finns went through a slow growth phase (0.5-5% 
growth per generation), and then a more recent fast growth phase (8-30% growth per 
generation); there was gene flow from the NFEs to the Finns. 
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Figure 4.3: Agreement of empirical allele frequency spectra with the modeled spectra. 
Sample sizes are 843 for the Finns and 820 for the NFEs. (A) Synonymous variants and (B) 
Missense variants.  
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Specification of a range of disease models 
Protein-coding variation will only partially explain the phenotypic variation of any 
polygenic trait. However, to focus on the role of coding variation (as they are more likely to 
enrich for functionally significant alleles), we simulated a heritable quantitative trait (h2 = 80%) 
for which aggregated coding variation in each of 1,000 genes explains, on average, 0.1% of total 
heritability. We assume selectively neutral missense variants are background variants with no 
effects on the trait, while selectively non-neutral missense variants are the causal variants. Four 
different disease models were generated by varying the degree of coupling (τ) between a causal 
variant’s phenotypic effect and the strength of purifying selection against that variant23. Broadly, 
M1 (τ=0) is characterized by rare and common alleles that have similar effects on phenotype; M2 
(τ=0.5) produces a modest correlation between variant frequency and effect size; and M3 (τ=1) 
results in a sharp inverse correlation. M4 (τ is randomly chosen among 0, 0.5 and 1 for each 
effect gene) may represent a more realistic scenario, as different genes are likely to have 
different pleiotropic effects and are therefore exposed to different strengths of purifying 
selection. As expected, we observed that as τ increases, more phenotypic variance is explained 
by rare variants (Figure S4.4).  
 
Alterations in allele frequency in the founder population 
With simulated data we demonstrated alterations in allele frequency in the founder 
population, which could potentially increase power of rare variant tests. We first showed that 
there is greater homogeneity of rare variation at any individual locus in a founder population. 
The Finns have on average 2.5x fewer rare variants (<5%) per gene compared to the NFEs (mean 
20.0 ± 4.5 vs. 52.3 ± 7.4).  This reduction in rare variants was seen for both variants we 
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simulated as causal and those simulated as neutral, background variants (Figure S4.5). As seen in 
Figure S4.6, the cumulative allele frequency of causal variants and background variants per gene 
is similar between the Finns and the NFEs, meaning that there are fewer rare variants in the 
Finns, but they are each on average more common than variants in NFEs.  
We next showed that there is increased frequency of causal variants (thus variance 
explained per gene) at some genes. We observed that the distribution of the variance explained 
per gene is wider in the Finns than in the NFEs (Figure 4.4). At one end of the distribution (the 
left tails of the graphs in Figure 4.4), the increased frequency of some individual causal variants 
leads to a greater variance explained for some genes in the Finns (more obvious with larger τ); at 
the other end of the distributions, so many causal variants are lost in Finland so other genes have 
lower variance explained in the Finns. As a result, some genes will be detectable in smaller 
sample sizes in Finns than in NFEs, whereas it will be more difficult to detect the effects of rare 
variation in some other genes, as too many causal variants have been lost due to the founder 
effect.  
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Figure 4.4: Distribution of variance explained per gene. Distribution of variance explained 
per gene by variants with MAF below 5% under four different disease models in either 30,000 
Finns or 30,000 NFEs. (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly 
sampled from 0, 0.5, and 1 for each effect gene). 
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Founder population vs. non-founder population in exome sequencing studies 
With simulated genotype and phenotype data, we compared the power of using 30,000 
NFEs and 30,000 Finns in exome sequencing studies under different disease models. We 
implemented five gene-based tests (T1, T5, MB, VT, SKAT-O) and single variant tests. Because 
we are interested in the role of lower frequency variants, all tests were run on variants with MAF 
below 5%. In the context of exome sequencing studies, the significance threshold for calculating 
power is set at α=2.5×10-6 (after Bonferroni correction, assuming 20,000 genes in the exome).  
As seen in Figure 4.5, as τ increases, so does the power from using Finns compared with 
using NFEs (compare panels A, B and C). Under M4, the biggest power gain in the Finns is seen 
among genes of which τ value is 1 (Figure S4.7). As the value of τ increases, phenotypic impacts 
of rare variants increase (Figure S4.4). Therefore it is more powerful to use a founder population 
in models where rare variation plays a more prominent role. These results are consistent with the 
effect of a founder event on allele frequencies – founder effects impact rare variants more than 
common variants. 
 
 
 
 87 
 
Figure 4.5: Power of exome sequencing studies in 30,000 Finns vs. 30,000 NFEs. 
 (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly sampled from 0, 0.5, and 1 
for each effect gene). We simulated a quantitative trait (h2 = 80%) for which aggregated coding 
variation in 1,000 genes explains the total heritability. Models M1-4 were generated by varying 
the degree of coupling (τ) between a causal variant’s phenotypic effect and the strength of 
purifying selection against that variant. We compared SKAT-O, variable threshold test (VT) and 
single variant tests (singleVar). 
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Understanding the excess of power in the founder population  
To understand why there is an excess of power in the founder population across different 
disease models, we considered genes detected in one population only. We observed that genes 
detected only in the Finns tend to have greater variance explained per gene in the Finns vs. the 
NFEs (Figure S4.8), while the opposite is true for genes detected in the NFEs only (Figure S4.9). 
For genes detected in the Finns only, the cumulative allele frequency for background variants is 
similar between the Finns and the NFEs, but the cumulative allele frequency for causal variants 
is shifted upwards in the Finns (Figure S4.10). For genes detected in the NFEs only, the opposite 
is true (Figure S4.11).  
As shown above, overall frequency rise of causal variants and thus greater variance 
explained for some genes could drive the excess of power in the Finns. We next tested whether 
reduced heterogeneity could also contribute to the power difference. We selected a set of genes 
for which the variance explained is closely matched between the NFEs and the Finns (Figure 
S4.12). As shown in Figure S4.13, the accumulated allele frequency of causal variants and 
background variants are similar between the two populations as well. The power gain in the 
Finns is retained under M3 (Figure S4.14), suggesting that reduced genetic heterogeneity alone 
could increase power when variance explained at a gene stays the same in the founder 
population. This effect is clearer when τ value is 1, as rare variants play a more prominent role. 
 
Relative power of different association tests for rare variants in a founder population 
Among the five gene-based tests we conducted, SKAT-O and VT tests perform best 
across a range of models in both the Finns and the NFEs (Figure 4.5, S4.15), as SKAT-O allows 
different variants to have different directions and magnitude of effects and VT decreases 
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background noise by selecting an optimal frequency threshold. The single variant test performs 
reasonably well under different disease models and it is particularly powerful when τ is large, 
especially when used in a founder population (Figure 4.5, S4.15). As τ increases, the effect sizes 
of rare causal mutations tend to increase, making it more powerful to test these variants 
individually.  For a founder population like the Finns, as we have shown earlier, the allele 
frequency spectra are shifted away from the rarest variants, which gives extra power in testing 
rare variants individually.  
Of note, LD has not been taken into account in both the single variant and gene-based 
tests. For gene-based tests, LD is generally not addressed, at least for discovery of gene-wide 
association signals. For single variant tests, we have operated under the assumption that the 
causal variants are directly assessed. Incorporating LD might further increase the power of single 
variant analyses, if one or more very rare variants were tagged by a single more common variant. 
 
Exome chip studies vs. exome sequencing studies 
Exome chip genotyping, despite being a much cheaper technology than exome 
sequencing, has not been rigorously assessed in terms of cost-efficiency. Here we used our 
simulation framework to try to address this question. We first confirmed that our simulations 
reproduced the expected differences in observed allele frequency spectra between exome chip 
and exome sequence data (Figure S4.16, compare with Figure 4.3B). We then compared the cost-
efficiency of exome chip studies and exome sequencing studies under different disease models in 
the Finnish founder population. The cost of exome chip per sample was assumed to be about one 
tenth that of exome sequencing. Figure 4.6 shows that under M4, the power of SKAT-O is far 
greater in exome chip studies than exome sequencing studies at a fixed cost (middle versus 
 90 
bottom line); in a fixed number of samples, however, genotyping arrays miss a substantial 
portion of causal variation detected in sequencing (top versus middle line). We also compared 
the two study designs in a non-founder population (Figure S4.17), under M1-3 (Figure S4.18, 
S4.19), as well as using different rare variant association tests (Figure S4.18), and observed 
similar results. Despite substantial cost-efficiency, the exome chip is underpowered to detect the 
contributions of certain genes simply because not enough causal variants in these genes are 
covered by the chip. This becomes more apparent as τ increases (Figure S4.19), because the 
allele frequency spectrum of causal variants shifts downwards, and the exome chip captures 
fewer casual variants (Figure S4.20). 
As Finnish samples contributed to exome chip design, we went on to assess how much 
their inclusion impacts the power of the exome chip in Finns, i.e., how the exome chip would 
perform in a non-Finnish founder population.  To address this question, we simulated a different 
exome chip, with no contribution of Finnish samples (replaced with an equal number of NFE 
samples). As expected, the power for rare variant association in Finns decreases when Finns 
were not used in the SNP discovery process of the exome chip. The power decrease was minimal 
at low sample size, reaching a difference of approximately 2% when 30,000 samples were used 
(Figure S4.21; the power dropped from ~10% to ~8% when Finns were not used). This suggests 
that the current exome chip would perform slightly less well in a non-Finnish founder 
population. However, the exome chip is still a far more cost-efficient strategy for such 
populations compared to exome sequencing, the power of which at a comparable cost (bottom 
line in Figure 4.6) is negligible. If it is desirable to avoid the marginal loss of power in non-
Finnish founder populations of interest, one could perform exome sequencing using a 
representative population sample first, and supplement the exome chip with the newly 
 91 
discovered variants to ensure that rare variation in that founder population is directly represented 
on the chip. 
 
Figure 4.6: Power of exome chip study vs. exome sequencing study in the Finns. The 
comparison was done under M4 using SKAT-O test. As different genes are likely to have 
different pleiotropic effects and are therefore exposed to different strengths of purifying 
selection, M4 is generated to represent a potentially more realistic scenario. The top two lines 
show power comparison at a fixed sample size; the bottom two lines show power comparison at 
a fixed cost (and thus only a tenth of the samples were sequenced). 
 
 
 92 
DISCUSSION 
By using forward simulations based on empirical deep resequencing data, we showed that 
1) founder populations can provide additional power, especially when the phenotypic effects of 
variants are tightly coupled with effects on fitness; 2) in a founder population, the single variant 
test, SKAT-O and VT perform best under different disease models, and the single variant test is 
particularly powerful when the phenotypic effects of variants are tightly coupled with effects on 
fitness; and 3) exome chip genotyping is currently much more cost-efficient than exome 
sequencing, but misses a substantial portion of causal variation in a sequencing study of the same 
sample size. We also suggest that more than 10,000 samples will likely be required to reach non-
negligible statistical power to identify associations with low frequency variation, assuming a per-
gene contribution of ~0.1% of heritability. This is consistent with recent independent estimates 
of required sample sizes11,24. We are almost certainly underestimating the required sample size, 
as we modeled a highly heritable trait where all heritability is explained by coding variants in 
1,000 genes, while the average contribution of coding variation to heritability will likely 
typically be lower than 0.1% per gene.  
The changes in allele frequency and decreased allelic diversity in founder populations 
that are caused by the bottleneck event(s) and drift can aid in detection of rare variant 
associations.  We have shown through our simulation that the power gain in the founder 
population is from both increased frequency of causal variants (thus variance explained per gene) 
at some genes and reduced genetic heterogeneity. Founder populations typically also 
demonstrate a higher degree of cultural and environmental homogeneity (not modeled here), 
which could further increase the strength of the genetic signals. However, there are also 
limitations with using founder populations. First, the population size may not be large enough to 
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allow for the collection of sufficiently large numbers of cases. Second, rare variants may be 
recent in origin and hence specific to a single founder population; these are the variants that are 
potentially least replicable, although this concern is less relevant for gene-based “burden”-type 
tests where variants are aggregated. Of note, the variants might be unique to founder populations, 
but the finding of genes is relevant to all populations. Third, a higher rate of direct and cryptic 
relatedness in some founder populations could confound baseline assumptions of independence 
among genotypes and phenotypes and may require more specialized approaches to account for 
this sample structure. Fourth, there might not be enough power to detect some genes in the 
founder population due to loss of causal variants (Figure 4.4). Nevertheless, the increased power, 
particularly for single variant tests, suggests that exome chip and/or exome sequencing in all 
available samples from founder populations would be an efficient use of resources. Different 
founder populations will happen to be better powered for different genes (in each population, 
certain genes will gain in power while others lose power, but the genes that gain in power will 
vary across populations).  Thus, a potentially attractive strategy for rare variant studies is to 
employ a diverse panel of well-powered founder populations. 
We evaluated a variety of statistical tests that were developed using different assumptions 
about genetic architecture.  We have shown that these tests are indeed sensitive to different 
disease models. SKAT-O and VT tests outperform the other gene-based tests across a range of 
different genetic architectures. It is also worth noting that single variant tests perform as well as 
or better than SKAT-O and VT, particularly in founder populations with decreased allelic 
diversity. This raises as one possible strategy to use single variant tests as a screen in founder 
populations and then follow up with candidate gene sequencing. 
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We have shown exome chip genotyping studies are currently much more cost-efficient 
than exome sequencing studies under a range of genetic models. In a fixed number of samples, 
however, exome chip genotyping studies miss a substantial portion of causal variation that could 
be detected by sequencing. Continued sharp drops in the cost of sequencing and/or targeted 
sequencing to follow up initial results might enable better-powered and more cost-efficient 
exome sequencing or whole genome sequencing studies. Given the requirement for large sample 
sizes, the ability to combine studies for example in meta-analyses will be critical for a new wave 
of discoveries.  Of note, as reference panels for imputation become larger and represent more 
populations, imputation of rare variants into samples with existing genotype data is another 
likely complementary approach for future studies.  
Our study has a number of limitations. We have taken a forward-in-time approach for 
simulating population sequence data, which has substantial advantage in terms of being able to 
model different genetic architectures and demographic parameters, but this approach comes with 
the cost of requiring greater computational resources. Because of this limitation, as well as the 
complexity of the demographic models, we did not do a complete search through the entire 
parameter space for the best-fitting demographic model. Another limitation with our simulation 
is that the limited sample size of the empirical data provided an incomplete view of rare variants 
in the population, so our simulations may not be completely accurate at very low allele 
frequencies. Moreover, as suggested by Casals et al.25, there might be a relaxation of selection in 
the founder population, which we have not considered in our simulation. It is also worth noting 
that our empirical Finnish samples are from all across Finland (Table S4.2) and therefore our 
model for simulating the Finns ignored the demographic heterogeneity within Finland. As deeper 
and richer human genetic data becomes available, the models can be calibrated and improved. 
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Last but not least, our study does not explore the effects of properties such as gene size or 
mutation rate on power, nor does it characterize power of rare variant tests at non-coding loci, 
where causal variant frequencies and effect sizes may be different. 
In summary, our study has highlighted the usefulness of understanding the population-
genetic properties of a study population to explore a range of genetic models and recognize the 
features and limitations of different association study designs in that population. As the field of 
human genetics moves forward to explore new and expanded sources of variation, such models 
offer a context with which to interpret the data and to plan future studies for gene discovery.  
With current approaches focused on rare variation, our work suggests that founder populations 
such as Finland can play an important role in genetic studies. 
 
MATERIALS AND METHODS 
Empirical Exome Sequencing Data 
We used whole exome sequenced samples from GoT2D (Genetics of Type 2 Diabetes) 
Project. In total, 2850 European type 2 diabetes cases and controls from four cohorts (DGI, 
FUSION, GoT2D-UK, KORA) were whole exome sequenced at ~40X. Exome target capture 
was performed with the Agilent SureSelect Human All Exon hybrid selection kit and sequence 
obtained on HiSeq. Subsequent alignment and allele calling used Burrows-Wheeler Aligner 
(BWA)26 and Genome Analysis Tookit (GATK)27. We kept samples from GoT2D-UK and 
KORA as the NFE population and samples from FUSION (Table S1) as the Finnish population 
for our analyses. We excluded SNPs with any missing data in any individual, SNPs with Hardy-
Weinberg equilibrium (HWE) P < 10-5, and all nonautosomal SNPs. We carried out 
multidimensional scaling (MDS) to identify population outliers (Figure S4.22). We filtered out 
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relatives, for whom the estimated genome-wide identity-by-descent (IBD) proportion to alleles 
shared was >0.10. We also excluded individuals with inbreeding coefficient >0.05 or <-0.05. We 
estimated IBD sharing using PLINK’s ‘--genome’ option28 and estimated inbreeding coefficients 
using PLINK’s ‘--het’ option. All analyses were carried out on an LD-pruned set of SNPs 
obtained by using the PLINK option ‘--indep’, which recursively removes SNPs within a sliding 
window. The parameters for --indep are: window size in SNPs (50), the number of SNPs to shift 
the window at each step (5), and the variance inflation factor (VIF) threshold (1.8). The final 
dataset included 843 Finnish samples and 820 NFE samples. 
 
Simulation of Exome Sequencing Data 
Exome sequencing data were simulated using ForSim, a forward evolutionary simulation 
tool.20 The average gene coding length was set as 1500bp. We used a mutation rate per site of 
2x10-8 29–31 and a uniform locus-wide recombination rate of 2Mb/cM as in previous report22. We 
modeled the distribution of selection coefficients for de novo missense mutations by a gamma 
distribution32 (as in previous reports32,33, we assume that ~20% of missense sites are neutrally 
evolving).  
For modeling the NFEs, we used a conventional four-parameter model of the history of 
the European population with long-term constant size followed by a bottleneck and then by an 
exponential expansion (Figure 4.2)21. The four parameters used were:  (1) long-term ancestral 
effective population size; (2) bottleneck population size; (3) duration of exponential growth in 
generations; and (4) recent effective population size. We adapted parameters from a recent 
simulation that generated representative sequence data for European populations22. (see Figure 
4.2 for final parameter values) 
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We modeled the Finns as a founder population established by a small number of NFEs. 
The founding event was followed by a slow growth phase and a more recent fast growth phase 
(Figure 4.2). The demographic history parameters were fitted by comparing to empirical exome 
sequencing data. P(data|model) was calculated and used for model-fitting (see Supplemental 
Method for further discussion). We tested two other models, neither of which agreed with the 
empirical observations as well as our current model (Table S4.3). 
 
Simulation of Exome Chip Data 
         Exome chip data were generated based on simulated exome sequencing data. The process 
resembles that of the actual exome chip design (see URL for a description of SNP content and 
selection strategies). ~12,000 simulated exomes across 16 cohorts were pooled together. The 
cohorts were matched by ancestry and sample size with the real cohorts (except that non-
European samples were substituted by NFE samples).  Only missense variants observed three or 
more times in at least two datasets were selected. ~90% of the selected SNPs passed design and 
were used for the simulated chip. For simulating the exome chip without contribution of Finnish 
samples, all procedures are the same except that Finnish samples are replaced with an equal 
number of NFE samples.  
 
Simulation of Phenotypic Variation 
We simulated a quantitative trait (QT) with a target size of 1,000 genes and the 
heritability of 80%. For efficiency, we modeled the heritability as completely explained by 
coding variants and a large target size of 1,000 genes; power will scale with total heritability, 
fraction of heritability explained by coding variation, and inversely with target size. We modeled 
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additive genetic effects as well as environmental effects. We did not consider non-additive 
effects (dominant, recessive, epistatic, gene-environment interactions) in our simulations. The 
joint allele frequency spectrum of both the Finns and the NFEs is used when calculating 
heritability. The effect sizes are scaled so as to cap heritability at 80%. More specifically, 
variance explained by a variant is calculated as 2*MAF*(1-MAF)*p2, where p is phenotypic 
effect. We sum this up over all variants and to cap heritability (additive genetic variance) at 80%, 
effect sizes of all variants are adjusted by a uniform factor. 
We assume neutral missense variants have no effect on phenotype. For assigning effect 
sizes of causal variants (non-neutral missense variants), we implemented a range of possible 
mappings between a variant’s selection coefficient s (we modeled the distribution of selection 
coefficients for de novo missense mutations by a gamma distribution, so s is known for every 
variant in our simulated data) and its effect on phenotype (p). We model these mappings as: p=sτ 
*(1+ε) as suggested by Eyre-Walker et al23. Here, τ is the degree of coupling between p and s; ε 
is a normally distributed random noise parameter. In the case of common diseases of post-
reproductive onset, the role of natural selection on causal variants is not yet clear. Therefore we 
tested a range of scenarios: M1 (τ=0), M2 (τ=0.5), M3 (τ=1), and M4 (τ randomly chosen with 
equal probability among 0, 0.5 and 1 for each effect gene).  
For determining the direction of effect of causal variants on QT, we further assumed that, 
in each trait-affecting gene, 0-20% of the causal variants influence the QT in the opposite 
direction from the remaining causal variants. This assumption is based on two different 
arguments: (1) the vast majority of de novo amino acid mutations with a measurable effect 
reduce protein activity and gain-of-function mutations are much less frequent and are restricted 
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to specific residues or domains; (2) some genes, like APOB (MIM 107730) and PCSK9 (MIM 
607786)18,34, clearly illustrate a mixture of variants that affect QTs in both directions.  
 
Association Tests and Power Analysis 
We conducted five different gene-based tests on simulated data. Four burden tests – 
VT14, T1, T5, and MB16 -- were performed by running SCORE-Seq (See URL for details).  VT 
stands for variable-threshold test; T1 and T5 are fixed threshold tests and pertain to the threshold 
of 1% and 5% respectively; MB stands for Madsen and Browning. The mutation information is 
aggregated across multiple variant sites of a gene through a weighted linear combination and 
then related to the phenotype of interest through appropriate regression models. The weights can 
be constant (T1, T5, VT) or dependent on allele frequencies (MB). The allele-frequency 
threshold can be fixed (T1, T5, MB) or variable (VT). We also performed the unified optimal 
test SKAT-O using default weights35. SKAT-O is a data-adaptive test that includes both burden 
tests and SKAT17 as special cases. Single-variant tests were carried out using PLINK’s ‘--linear’ 
option. We limited our analysis to variants with minor allele frequency below 5%.  
The exome-wide significance threshold for gene-based tests is set at α=2.5×10-6 (after 
bonferroni correction, assuming 20,000 genes in the exome). Power is defined as the number of 
effect genes reaching genome-wide significance divided by the target size, which is 1000. The 
exome-wide significance threshold for single variant test is 0.05 divided by the number of 
variants tested (varying with sample size, excluding singletons and doubletons). The power of 
the single variant test is defined as the number of effect genes harboring genome-wide significant 
variant(s) divided by 1000. 
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THE OVERVIEW 
While some traits may be under positive or balancing selection, other traits and diseases are 
likely under negative selection because of their deleterious effects to the fitness of the patient. 
Even for putatively neutral traits, mutations could have pleiotropic effects on fitness and thus be 
selected against. Under the selective pressure, causal variants would be kept at a low population 
frequency. Therefore, rare variants at multiple loci may influence the complex disease risk1.  
Despite the potential importance of rare variants, testing for their association with diseases 
and traits is likely to be challenging2,3. Rare variants are individually of low frequencies and 
well-powered studies require large sample sizes. Unfortunately, performing whole-genome or 
whole-exome sequencing for large cohorts is still very expensive. This dissertation presented 
approaches in response to these challenges – we developed a cost-efficient pooled sequencing 
scheme for follow-up studies of candidate genes, and proposed a simulation framework for 
evaluating various designs of rare variant association studies (RVAS). 
In this concluding chapter, I first list the major findings of each of the studies presented in 
this dissertation, followed by a discussion of the broader implications highlighted by these 
studies. As most issues directly relevant to each study have already been presented in the 
discussion section of each chapter, this section will be kept relatively brief. Finally, this chapter 
will conclude with a more general discussion on the potential outcome of RVAS. 
 
MAJOR FINDINGS 
Chapter 2 
 We developed a cost-efficient pooled sequencing scheme with well-controlled 
false-positive and false-negative rates. 
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 We identified three cases with known pathogenic variants in PTPN11, highlighting the 
possibility that Noonan syndrome may be an underdiagnosed cause of short stature. 
 The vas majority of HGMD-reported disease-causing dominant mutations did not 
manifest with the associated clinical phenotype in our cohort, suggesting that the 
classification of these variants as pathogenic is probably erroneous. 
 We reported a new frameshift mutation in IGF1R and demonstrate its pathogenicity by 
functional studies. 
 
Chapter 3 
 We identified heterozygous NPR2 mutations in ~2% of short stature patients; family 
analysis demonstrated segregation of these variants with the short stature phenotype. 
 We screened for NPR2 mutations in two cohorts of samples at the extremes of height 
distribution in population-based cohorts. 
 Heterozygous NPR2 mutations in NPR2 could be an important cause of nonsyndromic 
familial short stature. 
 
Chapter 4 
 We have developed a population genetics framework to assess the impact of the 
Finnish population history on genetic studies of rarer variation; more generally, our 
simulation approach provides a framework to evaluate association study designs in 
different study populations. 
 We demonstrate that power for rare variant association tests is higher in the Finnish 
population, especially when variants’ phenotypic effects are tightly coupled with 
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fitness effects. 
 SKAT-O, VT, and single variant tests are more powerful than other rare variant 
methods in a founder population.  
 At a fixed cost, genotyping strategies have far greater power than sequencing; in a 
fixed number of samples, however, genotyping arrays miss a substantial portion of 
causal variation detected in sequencing. 
  
BROADER IMPLICATION OF THE STUDIES 
Ongoing RVAS attempts a search for genes harboring multiple rare variants collectively 
associated with complex traits. The power of such studies depends on three key quantities: the 
combined allele frequency of the tested alleles, the excess relative risk of disease conferred by 
alleles in the class, and sample size. To maximize the power of an association study, we want all 
these quantities, to be as large as possible. Unfortunately, these goals sometimes pull in opposite 
directions. For example, expanding the alleles under study increases combined allele frequency 
but dilutes the excess relative risk4. 
 
The balance between combined allele frequency and the excess relative risk 
The association signal is provided by pathogenic variants, where as benign alleles are a 
source of noise masking the association signal. Ideally, one would aggregate only pathogenic 
alleles and ignore benign alleles. Unfortunately, one cannot perfectly distinguish the former from 
the latter. To enrich for harmful alleles, RVAS typically focuses on nonsynonymous variants in 
protein-coding regions, or focuses on variants with frequency below a specified threshold. Even 
with these limitations, the resulting variants remain a mixture of pathogenic and benign alleles. 
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Several potential directions to optimize the balance between combined allele frequency and the 
excess relative risk can be pursued. 
 
Functional characterization of human allelic variants 
The ability to discriminate between pathogenic and benign alleles would dramatically 
increase the potential of sequencing studies focusing on rare variants in complex traits. Several 
studies have demonstrated that highlighting functional variants using experimental5,6 or 
computational7–9 approaches increase the power of these studies. 
Medical genetics is interested in finding “pathogenic” mutations that causally influence 
traits of interest. Population genetics focuses on “deleterious” alleles that are under purifying 
selection. Functional analysis is focused on the “damaging” effect on molecular function. The 
rationale for current approaches that infer functional significance of human allelic variants is that 
the effects on phenotypes correlate with the effects on fitness and are mediated by the effects on 
molecular function. Yet it is possible that most of human alleles under purifying selection have 
no detectable effects on medically relevant phenotypes in current environment, and damaging 
alleles may be neutral or beneficial rather than deleterious10. Below we review major prediction 
methods and discuss the limitations or future direction for each. 
1. Allele frequency as a proxy 
The analysis of allele frequency in unaffected controls has been used in many studies to 
enrich for pathogenic variants. This approach has been dramatically facilitated by large-scale 
sequencing efforts such as 1000 Genomes Project11 and Exome Sequencing Project (ESP)12. It is 
easy to infer that the variant is benign (or, at least, not of high penetrance) if it is seen at 
appreciable frequency in healthy controls, yet the sole observation of its absence in multiple 
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controls is insufficient to convincingly imply pathogenicity. Other limitations include 
imbalanced number of cases and controls in some studies and no phenotype information for 
sequenced individuals in public datasets such as 1000 Genomes and ESP. 
2. Experimental evidence 
Direct experimental functional analysis is a highly convincing method to test the effect of 
human allelic variants, which includes the analysis of protein expression and localization, in 
vitro functional assays and genetic manipulation on model organisms. The limitations with direct 
experimental methods are that: they are highly laborious and not feasible, at least currently, at 
the whole-exome scale; it is not always easy to find functional assays that are informative about 
the human condition.  
3. Computational predictions 
Computational programs, such as PlolyPhen-213, SIFT14, or Mutation Taster15, offer 
predictions of whether a mutation is likely to be damaging. Prediction methods mostly rely on 
two fundamental observations. First, the analysis of phylogenetic information in the form of 
multiple sequence alignment is a powerful source of information about the spectrum of residues 
allowed at particular positions of the protein of interest. Second, mapping mutations on protein 
3D structure may provide key insights into the functional mechanisms, if the structure has been 
resolved for the protein of interest or its close homolog10.  
At this time, the accuracy of computational predictions is ~75-80%, which is less 
informative than direct experimental evidence10. However, given that computational methods do 
not involve any additional labor and cost and can be applied to any gene, they will likely 
continue to be used widely in the future. On the one hand, as more protein sequences and 
structures accompanied by training data (known disease-causing mutations and neutral 
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polymorphisms) are available, the classification accuracy will improve. On the other hand, the 
accuracy can be potentially improved if the scope of the methods would be narrower, so they 
would be specifically focused on a single phenotype and a group of genes involved in this 
phenotype.  
 
Extending RVAS to noncoding regions 
By extending RVAS to noncoding regions, more pathogenic variants can be included in the 
association tests. A major challenge, though, is how to select the genomic regions across which 
to aggregate variants. To perform RVAS with reasonable sensitivity in noncoding regions, it will 
be important to have fairly precise knowledge of the functionally important regulatory sequences 
related to each human gene to aggregate them together.  
At present, without such knowledge, it is more cost-efficient to perform whole-exome, 
rather than whole-genome sequencing studies. This approach will maximize the number of 
samples that can be analyzed for coding regions, where the power is currently vastly greater, 
where the effect sizes are expected to be larger, and where the discoveries are likely to be more 
immediately actionable.  
 
Using founder populations 
Another approach is to use populations in which the combined allele frequency of casual 
variants for some genes happens to be much larger than other populations. As we have shown in 
Chapter 4, the distribution of combined allele frequency of causal variants is wider in the Finns 
compared to the non-Finnish Europeans. Studying recently bottlenecked populations such as 
Finland will make it easier to discover some disease-associated genes, although the power for 
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detecting some other genes will be decreased. Studying multiple founder populations may be a 
powerful strategy. The discoveries might be incomplete, but they may prove valuable by 
providing the initial insights into disease pathogenesis and architecture.  
 
Enabling studies of larger sample size 
Extrapolation of effect sizes and frequencies from published candidate gene studies shows 
that thousands of individuals are required for whole exome sequencing studies to reach 
acceptable statistical power16. In Chapter 4, we showed that more than 10,000 samples will likely 
be required to reach non-negligible statistical power to identify associations with low frequency 
variation (assuming a per-gene contribution of ~0.1% of heritability). This is consistent with 
recent independent estimates of required sample sizes based on population genetics 
simulations3,4. 
The cost of sequencing a human genome is dropping rapidly, due to the continual 
development of new, faster, cheaper DNA sequencing technologies such as next-generation 
DNA sequencing. Prices are expected to drop further over the next few years, with new DNA 
sequencing methods currently under development, such as nanopore DNA sequencing17–19 and 
microscopy-based techniques20. However, at this time, whole-genome sequencing or even 
whole-exome sequencing is too expensive to perform for large sample sizes. A few 
techniques/designs could fill the niche between genome-wide CVAS and whole-genome 
sequencing.  
 
Exome chip 
The exome chips provide an economical method to assay a large number of coding variants 
 113 
and investigate the role of rare DNA variants in causing disease. As we have shown in Chapter 4, 
at a fixed cost, exome chip has far greater power than exome sequencing, though in a fixed 
number of samples, exome chip misses a substantial portion of genetic signals detected in 
sequencing. 
A limitation of exome chips is that they will miss a significant fraction (~15-20%) of 
variants whose genomic context is incompatible with array-based genotyping, variants highly 
specific to non-European populations, as well as the rarest variants in any population21. While 
these exome chip studies will only provide an imperfect approximation to the results of 
sequencing studies, they will provide a preview of the discoveries that will be possible when 
exome sequencing is performed on hundreds of thousands of samples. Given that over a million 
and a half exome chips have been sold, we are expecting to see interesting findings coming out 
of these studies especially when methods such as meta-analysis is applied to combine studies. If 
it turns out that large exome chip studies don’t provide a lot of insight, there are two possible 
explanations: either coding variants have much smaller effect sizes than expected; or it’s really 
the rarest variants missed by exome chip that are important. 
 
Imputation 
When a very large number of individuals with both exome sequence data and genome-wide 
genotype data are available, statistical imputation can also be a fast and economical strategy for 
extending sample sizes. Currently, sufficiently large reference panels that can support imputation 
of very rare variants are not available for most cosmopolitan populations. However, several 
examples of the success of this approach exist, mainly from the isolated population of Iceland. 
There, relatively limited genetic diversity, a panel of sequenced Icelanders, and the availability 
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of a large collection of genotyped individuals have enabled recent discoveries using imputation. 
MYH6 L721W (minor allele frequency 0.4%) was evaluated in 38,000 individuals and 
associated with risk for sick sinus syndrome22 and APP A673T (minor allele frequency 0.1%) 
was evaluated in 71,000 individuals and associated with the risk for Alzheimer’s disease23. 
 
Target enrichment and sample pooling 
One popular efficient design for Genome-wide CVAS is the two-stage design. The first 
stage employs a whole-genome genotyping platform and tests all available markers for 
association with the disease, while the second stage uses a custom genotyping platform to follow 
up those markers exhibiting sufficiently strong association with the disease in the first stage. 
Two-stage designs gain their efficiency by excluding markers for further testing that show little 
evidence of association in the first stage24. Genome-wide RVAS will likely continue using 
two-stage designs, with exome sequencing or exome array genotyping used in the first stage. A 
range of approaches are available for follow-up in the second stage, ranging from genotype 
imputation to targeted genotyping or targeted sequencing. When targeted genotyping and 
imputation are not possible or when the association signal is driven by a burden of rare mutations, 
it will be necessary to undertake targeted sequencing of genes prioritized in the first stage. 
Target enrichment can be a highly effective way of reducing sequencing costs and saving 
sequencing time. Conversely, target enrichment increases sample preparation cost and time. 
Assuming that the throughput of sequencing runs and our ability to analyze large whole genome 
sequencing datasets both continue to increase, and the cost per base of sequence continue to 
decrease, there will come a point at which it is no longer economical to perform target 
enrichment of individual samples, compared to whole genome sequencing25.  
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The cost of performing target enrichment can be reduced by pooling samples before 
enrichment. In Chapter 2, we demonstrated that our pooled sequencing scheme reduces cost 
considerably and is well suited for follow-up studies on candidate genes. Several potential 
directions to further improve or extend the use of the approach can be pursued. First, technology 
development is needed for methods more readily scalable for different target sizes and different 
sample sizes. Second, downstream analysis methods for pooled sequencing need to be further 
improved. Existing methods for aggregate rare variant statistics are not designed to work well 
with pooled sequencing data, which lose individual genotype information and are more prone to 
errors compared to high-coverage individual sequencing. 
 
OUTLOOK FOR RVAS 
The combined contribution of multiple rare loci to the population-level genetic variance 
remains an open question because association studies that focus on rare variants remain 
underpowered. The few population-based common disease exome-sequencing studies published 
to date, have not been successful in finding individual genes showing significant enrichment26,27. 
These current findings are likely to foreshadow the definitive identification of individual genes 
in larger cohorts, following the trajectory of genome-wide CVAS. 
Although effect sizes for rare variants may be larger than for common variants, large effect 
sizes or odds ratios do not equate to a large contribution to the variance explained at the 
population level. Recent sequencing studies identified enrichment of rare variants, but this early 
work suggests a large polygenic burden of rare coding variants, which alone may not account for 
the unexplained variation28,29.  
Methods for detecting contribution of common variants to the missing heritability have been 
described previously. Purcell et al.30 developed the concept of a polygenic score by combining 
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the effects of multiple common variants that are modestly associated with schizophrenia. They 
showed that the score is predictive of schizophrenia in an independent cohort, thus indicating 
that there is polygenic signal from many yet-to-be-detected common variants in schizophrenia. 
Yang et al.31 adopted a different approach by estimating the proportion of variance for human 
height explained by hundreds of thousands of common variants with a linear-model analysis. 
They found that at least 45% of the variance can be accounted for by common variants, 
indicating that there are many common variants associated with height that have yet to be 
discovered. 
More recently, methods have been designed to detect the signal of polygenic inheritance 
from low-frequency variants. Chan and colleagues showed that there is more power to detect risk 
variants than to detect protective variants, resulting in an increase in the ratio of detected risk to 
protective variants. Such an excess can also occur if risk variants are present and kept at lower 
frequencies because of negative selection. They tested the method on published GWAS results 
and observed a strong signal in some diseases (schizophrenia and type 2 diabetes) but not 
others32.  
Agarwala et al. developed a population genetics framework to directly simulate, in large 
populations, a wide space of genetic architecture. Each hypothesis about genetic architecture was 
then quantitatively evaluated against cumulative results of empirical studies already performed. 
Whereas extreme models are excluded by the combination of epidemiology, linkage and 
genome-wide association studies, many models remain consistent, including those where rare 
variants explain either little (<25%) or most (>80%) of type 2 diabetes heritability33. 
 Overall, the genetic architecture will be different from one complex trait to another. Even 
within one trait, there will be heterogeneity in phenotypic contributions across loci. Mutation rate, 
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overall phenotypic contribution, coupling between phenotypic effects and fitness effects and 
allelic spectrum of causal variants are all likely to vary across loci. Thus, outcomes of RVAS 
will be different for different traits. Ongoing sequencing and genotyping studies will further 
constrain the space of possible architectures, but very large sample sizes will be required to 
localize most of the heritability underlying complex traits. This is not an either-or debate, and 
advocating a focus on solely rare or common variants will not be a productive way forward. 
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Supplementary Material – Large-scale pooled next-generation 
sequencing of 1077 genes to identify genetic causes of short stature 
Supplemental Methods – Variant Calling Strategy 
Variant calling was performed using Syzygy software and then applied a new likelihood-
based secondary calling strategy that integrated the extra information from our matrix design. 
Instead of setting a hard cutoff for calling variants in individual pools as typically implemented 
in Syzygy, we calculated accumulated evidence for the presence of the variant allele from the 
full matrix. To keep the false positive rate low, we also required supportive evidence for an 
individual variant to be present in both row and column pools. 
Specifically, our single nucleotide polymorphism (SNP) calling strategy is a likelihood 
ratio test comparing the following two hypotheses: 1. Null Hypothesis (H0) – there is no variant 
at the site; observed non-reference reads are all due to sequencing error. 2. Alternative 
Hypothesis (H1) – there is a variant at the site (as well as background sequencing error rate). 
First, a sequencing error rate is chosen to optimize the likelihood of the null hypothesis (L[H0]); 
then a background sequencing error rate as well as variant frequencies (in pools where there are 
reads of the variant allele) are chosen to optimize the likelihood of the alternative hypothesis 
(L[H1]). The test statistic D is calculated as: D = 2*(ln(L[H1]) - ln(L[H0])). The probability 
distribution of D is approximately a chi-square distribution with degrees of freedom equal to 
df[H1]-df[H0] (in our case, the degrees of freedom is equal to the number of pools with non-zero 
estimated variant frequency). We can then derive the p-values and significance was set at 0.05 
after a strict Bonferroni correction accounting for the number of sites tested. 
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Figure S2.1: Electropherogram of novel IGF1R variant #1, c.418dupG (see Table 2.3). (A) 
Schematic of the IGF1R peptide is shown above the correlating coding exons (numbered 1 to 
21). Arrow indicates the location of the variant. The IGF1R peptide consist of a signal peptide, 
alpha and beta subunits, composed of the following subdomains: L1, receptor leucine-rich 
domain; CR, cysteine-rich, furin-like, domain; L2, receptor L domain; FN, fibronectin type III 
domain; TM, transmembrane domain; TK, tyrosine kinase catalytic domain; and CT, C-terminal 
domain. (B) Electropherogram of IGF1R c.418dupG (exon 2) in Patient genomic DNA. Box 
nucleotide, c.418. Normal and new residues generated by the c.418dupG, are as indicated.  
Asterix (*), stop codon. 
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Figure S2.2: Matrix pooling design. Each box in the table represents one sample, which is 
present in one column pool and one row pool.  Four empty “holes”, labeled as yellow stars, were 
included into each matrix for assessing false positive rate. 
 
 
 
 
 
Table S2.1: Human Gene Mutation Database Dominant Disease Associated Variants Found in Cases Only 
 
Gene Disease HGMD 
Variant ID 
Genomic 
Location (hg19) 
c.DNA Protein Ref. Subject Description 
PTPN11 Noonan 
syndrome 
CM024733 chr12:112910844 NM_002834.3:
c.853T-C 
NP_002825.3:
p.F285L 
1 See main text. 
PTPN11 Noonan 
syndrome 
CM021136 chr12:112915526 
 
NM_002834.3:
c.925A-G 
NP_002825.3: 
p.I309V 
1 See main text. 
PTPN11 Noonan 
syndrome 
CM013416 
 
chr12:112888172 
 
NM_002834.3:
c.188A-G 
NP_002825.3: 
p.Y63C 
2 See main text. 
TRPV4 Brachyolmia CM083203 chr12:110230201 NM_021625.4:
c.1858G-A 
NP_067638.3:
p.V620I 
3 See main text. 
NLRP3 Familial cold 
auto-
inflammatory 
syndrome 
CM043481 chr1:247588214 NM_004895.4:
c.1469G-A 
 
NP_004886.3:
p.R490K 
 
4 ISS. No report of recurrent rash or 
arthralgias with cold exposure.  
CREBBP 
 
Rubinstein-
Taybi 
syndrome 
CM021087 
 
chr16:3778387 
 
NM_004380.2:
c.6661A-C 
 
NP_004371.2:
p.M2221L 
 
5 GHD. Normal intelligence. No 
physical signs of Rubinstein-Taybi. 
CREBBP 
 
Rubinstein-
Taybi 
syndrome 
CM085347 
 
chr16:3820773 
 
NM_004380.2:
c.2678C-T 
 
NP_004371.2:
p.S893L 
 
6 GHD. Normal intelligence. No 
physical signs of Rubinstein-Taybi. 
GLI3 
 
Greig 
cephalopoly-
syndactyly 
syndrome 
CM970684 
 
chr7:42007506 
 
NM_000168.5:
c.2119C-T 
 
NP_000159.3:
p.P707S 
 
7 ISS, developmental delay. Normal 
head shape and no polydactyly or 
syndactyly. 
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Table S2.1 (Continued) 
 
GLI3 
 
Greig 
cephalopoly-
syndactyly 
syndrome 
CM990707 
 
chr7:42007201 
 
NM_000168.5:
c.2424A-G 
 
NP_000159.3:
p.I808M 
 
8 Dysplastic thumb with mild short 
stature. Variant does not segregate with 
phenotype in the family. 
FGFR1 
 
Non-
syndromic 
trigono-
cephaly 
CM010303 
 
chr8:38282064 
 
NM_023110.2:
c.899T-C 
 
NP_075598.2:
p.I300T 
 
9 ISS. Normocephalic. 
PTCH1 Holoprosence
phaly 
CM020752 chr9:98229479 NM_000264.3:
c.2479A-G 
NP_000255.2:
p.S827G 
10 Found in the subject with the novel 
IGF1R frameshift. No midline defects 
although has a bilateral cleft lip and 
palate. No GHD. 
JAG1 Alagille 
syndrome 
CM061804 chr20:10622447 NM_000214.2:
c.2666G-A 
NP_000205.1:
p.R889Q 
 
11 Patient has clinical diagnosis of 
Rubinstein-Taybi syndrome. No 
hepatic abnormalities. 
RPL5 Diamond-
Blackfan 
anemia 
CM086904 
 
chr1:93301840 
 
NM_000969.3:
c.418G-A 
 
NP_000960.2:
p.G140S 
 
12 ISS. No cleft palate, thumb 
abnormalities, or anemia.  
COL1A1 Osteogenesis 
imperfecta I 
CM123299 
 
chr17:48264220 
 
NM_000088.3:
c.3595A-G 
NP_000079.2:
p.S1199G 
13 ISS. No history of fractures.  
COL1A1 Ehlers-
Danlos 
Syndrome 
CM071624 
 
chr17:48265329 
 
NM_000088.3:
c.3277C-T 
NP_000079.2:
p.R1093C 
14 ISS. No skin hyperextensibility or joint 
hypermobility. 
EXT1 
 
Multiple 
osteo-
chondromas 
CM099178 
 
chr8:118830697 
 
NM_000127.2:
c.1609G-A 
NP_000118.2:
p.V537I 
 
15 ISS. No osteochondromas. 
INSR Diabetes CM950700 chr19:7141798 NM_000208.2:
c.2572A-G 
NP_000199.2:
p.T858A 
16 SGA. No signs of diabetes or insulin 
resistance.  
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Table S2.1 (Continued) 
 
COL11A1 Robin 
Sequence and 
Marshall 
syndrome 
CS030538 
 
chr1:103400613 
 
NM_080629.2: 
c.IVS45+3G4A 
 
Unknown. 
Predicted 
splice variant. 
17 Clinically diagnosed with Coffin-
Lowry syndrome. No cleft palate. 
ALPL Hypo-
phosphatasia 
CM084852 
 
chr1:21890638 
 
NM_000478.4:
c.577C-G 
NP_000469.3:
p.P193A 
NP ISS. No bone abnormalities. Normal 
alkaline phosphatase levels. 
ALPL Hypo-
phosphatasia 
CM993530 
 
chr1:21890587 
 
NM_000478.4:
c.526G-A 
NP_000469.3:
p.A176T 
18 ISS. No bone abnormalities. Normal 
alkaline phosphatase levels. 
ABCC8 Hyper-
insulinism 
CM994416 
 
chr11:17450177 
 
NM_000352.3:
c.1858C-T 
NP_000343.2:
p.R620C 
19 Hypopituitarism. No signs of 
hyperinsulinism.  
PHEX Hypo-
phosphatemic 
Rickets  
CM025296 
 
chrX:22051133 
 
NM_000444.4:
c.10G-C 
 
NP_000435.3:
p.E4Q 
 
NP ISS. Normal phosphorus levels and no 
rickets. 
NF1 Neurofibrom
atosis 1 
CM000785 
 
chr17:29552261 
 
NM_000267.3:
c.1994C-T 
NP_000258.1:
p.S665F 
20 GHD. No stigmata of 
neurofibromatosis. 
NF1 Neurofibrom
atosis 1 
CS040852 
 
chr17:29653237 
 
NM_000267.3:
c.5172G>A 
Unknown. 
Predicted 
splice variant. 
21  
BMP4 Orbicularis 
oris defect 
CM091521 chr14:54417117 NM_001202.3:
c.860G-A 
NP_001193.2:
p.R287H 
22  
TGFBR2 Marfan 
Syndrome 
CM063202 chr3:30733044 NM_003242.5:
c.1657T-A 
NP_003233.4:
p.S553T 
23  
LRP5 Osteoporosis, 
primary 
CM122876 chr11:68193464 NM_002335.2:
c.3446T-A 
NP_002326.2:
p.L1149Q 
24   
 
ISS – Idiopathic short stature. GHD – Growth hormone deficiency. SGA – Small for gestational age. NP – Not published.  
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Table S2.2: List of 1077 height candidate genes, including (1) genes known to 
underlie syndromic growth disorders or skeletal dysplasias, as well as genes 
involved in growth plate biology or growth hormone signaling (bold) (2) genes 
within genomic loci associated with height based on genome-wide association studies 
(plain) (3) genes belonging to both group (1) and (2) (underlined). 
 
AAMP$ CDSN$ GABRD$ LIN28$ PHOSPHO1$ SMARCA5$
ABCB5$ CENPO$ GALNS$ LIN28B$ PIGC$ SMARCAL1(
ABCB8$ CENPP$ GAP43$ LMBR1( PIGF$ SMC1A(
ABCC8$ CEP120$ GAS1$ LMNA( PIGK$ SMC3(
ABCE1$ CEP290( GCNT1$ LMO4$ PITPNM2$ SMO(
ABI3$ CETN3$ GDF5$ LMX1B( PITX1$ SMOX$
ABP1$ CHCHD7$ GDPD5$ LOXL1$ PITX2( SMPD1(
ACAN$ CHD1L$ GFM1$ LPAR1$ PJA2$ SMS$
ACBD4$ CHD7( GFPT2$ LPGAT1$ PKIA$ SNAP47(
ACPL2$ CHMP4A$ GGT7$ LRIG3$ PKN2$ SNED1$
ACSS2$ CHMP4B$ GH1$ LRP5( PLAG1$ SNF8$
ACTN1$ CHRNG$ GH2$ LRP6$ PLAGL1( SNRPC$
ACVR1( CHST3( GHR( LRRC37B$ PLCD3$ SOCS2$
ACY3$ CISH$ GHRH( LSAMP$ PLD1$ SOCS3(
ADA( CLCN5( GHRHR( LTBP1$ PLEKHA5$ SOCS5$
ADAM28$ CLDN22$ GHRL( LTBP2$ PLEKHJ1$ SOS1(
ADAMTS10$ CLIC4$ GHSR$ LTBP3$ PLOD2( SOST(
ADAMTS12$ CNOT6$ GIP$ LTK$ PLXNC1$ SOX2(
ADAMTS17$ COL10A1( GIPC2$ LUM$ PML$ SOX3(
ADAMTS2( COL11A1$ GIT1$ LUZP1$ PMPCA$ SOX5(
ADAMTS3$ COL11A2( GJA1( LXN$ PNKD$ SOX6(
ADAMTSL2( COL1A1( GJE1$ LY86$ PNPT1$ SOX9$
ADAMTSL3$ COL1A2( GKAP1$ LYPD1$ POLR2B$ SPAG9$
ADCY3$ COL2A1( GLB1( LYPLAL1$ POLR3A$ SPDEF$
ADCY4$ COL5A1( GLI2$ LYSMD3$ POLR3G$ SPG20(
ADRBK1$ COL5A2( GLI3( LYSMD4$ POMC$ SPINK2$
AEBP2$ COL9A1( GLT25D2$ MACC1$ POR( SRRM1$
AGPS( COL9A2( GMPR2$ MAL2$ POU1F1( SRY(
AGXT$ COL9A3( GNA12$ MAP2K1( POU5F1$ SSH3$
AK5$ COMP( GNAS( MAP2K2( PPA2$ SSR1$
AKAP7$ COPA$ GNPAT( MAP2K3$ PPAP2A$ SSSCA1$
ALG12( COX18$ GNPTAB$ MAP6$ PPM1A$ SST(
ALMS1( COX7A2$ GNRH1( MAPK1( PPP2R3A$ ST3GAL1$
ALPL( CPAMD8$ GNRHR( MAPK3( PPP2R5A$ STAG1$
ALPP$ CPEB4$ GPBAR1$ MAPK9$ PQBP1( STARD3NL$
ALPPL2$ CPN1$ GPC3( MAPKAPK3$ PRAM1$ STAT3(
ALX4( CRADD$ GPC5$ MATN3( PRB1$ STAT5B(
 129 
Table(S2.2((Continued)(
$ $ ( $ (
AMZ1$ CREB5$ GPC6$ MBOAT1$ PRDM12$ STAU1$
ANKH( CREBBP( GPR111$ MBTD1$ PRDM6$ STC1$
ANKRD13B$ CRIPT$ GPR115$ MC3R$ PREPL$ STC2$
ANKRD13D$ CROCC$ GPR126$ MC4R$ PRG4( STK10$
ANKRD17$ CRTAP( GPR135$ MCFD2$ PRKAB2$ STK25$
ANKS1A$ CSE1L$ GPR27$ MCM10$ PRKCD$ STK36$
ANO5( CSNK1G3$ GPR39$ MECP2( PRKCZ$ STOML1$
ANO7$ CTDP1( GPR98$ MED28$ PRKG2$ SUB1$
ANTXR2( CTPS$ GPSM1$ MEF2A$ PROCR$ SUCLG2$
AP3D1$ CTSK( GRK7$ MEF2C$ PROK2$ SUZ12$
AQP12A$ CUL4B( GRM4$ MESP2( PROKR2( SV2A$
ARFGEF2$ CUL7( GSDMC$ MEST( PROP1( SYN3$
ARHGEF3$ CXXC4$ GSS$ METRN$ PSMB3$ SYT12$
ARL6( CYP11B1( GTF2B$ METTL13$ PSORS1C1$ T$
ARPC2$ CYP19A1$ GTF2H5$ MFAP2$ PTCH1$ TAC3(
ARSB( CYP21A2$ GUSB( MGAT5$ PTCH2( TACR3(
ARSE( CYP27A1$ GYPA$ MGP( PTEN( TAF11$
ASS1$ CYP27B1( GYPB$ MICA$ PTGFR$ TAF2$
ASTN1$ DAAM1$ H1FX$ MKKS( PTH( TAL2$
ATAD2B$ DACT1$ H2AFY$ MKL2$ PTH1R( TAOK1$
ATG7$ DCN$ HABP4$ MKS1( PTHLH$ TARS$
ATG9B$ DDX27$ HACE1$ MLF1$ PTPDC1$ TAX1BP1$
ATP13A2$ DDX4$ HAGHL$ MLXIP$ PTPN11( TAZ(
ATP2B1$ DDX6$ HCCS( MMP13( PTPRJ$ TBC1D21$
ATP5SL$ DHCR24( HCP5$ MMP2( PXMP3$ TBCE(
ATP6V0A2( DHCR7( HDAC11$ MMP24$ PXMP4$ TBX1(
ATP7A( DHDDS$ HDLBP$ MMP9( QSOX2$ TBX10$
ATP8B1( DIS3L2$ HEMK1$ MNX1( RAB23( TBX15$
ATR( DLEU7$ HEPACAM2$ MOBKL2A$ RAB26$ TBX3(
ATRX( DLG5$ HESX1( MOS$ RAB3GAP1( TBX4$
ATXN3$ DLL3( HEXIM1$ MPHOSPH9$ RAB3GAP2( TBX5(
AURKA$ DLX3( HEXIM2$ MRPL42$ RAD23B$ TCF19$
B3GALTL( DNAJC27$ HFE$ MRPS16( RAD51L1$ TCF4(
B3GNT8$ DNM3$ HHIP$ MRPS6$ RAF1( TCOF1(
B4GALT7( DNMBP$ HIF1A( MSL2$ RAI1( TEAD1$
BAK1$ DNMT3A$ HINT3$ MSLN$ RARS$ TET2$
BBS1( DOCK2$ HIST1H2AE$ MSX2( RASA2$ TGFB1(
BBS10( DOCK3$ HIST1H2BG$ MTMR11$ RASGEF1B$ TGFB2$
BBS12( DOHH$ HIST1H3A$ MUSK$ RASGRP3$ TGFBR1(
BBS2( DOT1L$ HIST1H4A$ MUSTN1$ RASSF10$ TGFBR2(
BBS4( DPCR1$ HIVEP2$ MYC$ RAX2$ THRA(
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BBS5( DTL$ HK3$ MYCN( RBBP8$ THRB(
BBS7$ DYM$ HLAEDQA1$ MYH7B$ RBM15B$ TIGD1$
BBS9( E2F1$ HLAEDQB1$ MYO1E$ RBM28( TIGIT$
BCKDHA$ E4F1$ HLAEDRB1$ MYO6$ RBM45$ TIMP3$
BCKDHB$ EBP( HMGA1$ MYO9B$ RDH12$ TINF2$
BCL2L14$ ECM2$ HMGA2$ NARFL$ RECQL4( TLE3$
BCL7A$ EDEM2$ HNRNPK$ NBN( REST$ TLN2$
BCL9$ EFEMP1$ HOXA11( NCK1$ RFK$ TMBIM1$
BICD2$ EFHD1$ HOXA13( NCL$ RFT1$ TMEM176A$
BMP2$ EFNB1( HOXD13( NCOA1$ RFWD2$ TMEM181$
BMP3$ EFR3B$ HPRT1( NCOA6$ RFX6$ TMEM22$
BMP4( EIF2AK3$ HRAS( NCOR2$ RHOD$ TMEM30A$
BMP5( EIF4E2$ HS2ST1$ NCSTN$ RIPK3$ TMEM38B$
BMP6$ EIF4E3$ HSPG2( NDUFAF1$ RMI1$ TMEM91$
BMP7( EIF5AL1$ HTR1D$ NDUFB1$ RNF135$ TNC$
BMPR1A( EIF6$ HYAL1( NDUFV1$ RNF24$ TNFRSF11A(
BMPR1B( ENPP2$ ICK( NEDD8$ RNF7$ TNFRSF11B(
BMPR2( EP300( ID4$ NEK4$ ROR2( TNFSF10$
BNC2$ EPB41L1$ IDUA( NEU1$ RORA$ TNFSF11(
BPIL2$ EPB41L2$ IFT80( NF1$ RPL11( TNP1$
BRAF( EPDR1$ IGBP1( NFATC4$ RPL35A( TNPO1$
BRCA2$ EPHB2$ IGF1( NFIC$ RPL5$ TNS1$
BRUNOL5$ EPRS$ IGF1R$ NFKBIA( RPLP1$ TOX$
BTK( EPYC$ IGF2( NHLH1$ RPS10$ TP53I13$
BTN1A1$ ERC2$ IGF2BP2$ NIPBL( RPS17( TP53I3$
BTN2A1$ ERCC2( IGF2BP3$ NLRP3( RPS19( TP53INP2$
BUB1B( ERCC3( IGF2R( NMB$ RPS20$ TP63(
BVES$ ERLIN1$ IGFALS( NMBR$ RPS24$ TRA2A$
C12orf12$ ESCO2( IGFBP1$ NMU$ RPS6KA3( TRA2B$
C12orf65$ ESR1$ IGFBP2( NMUR1$ RPS7( TRAPPC2(
C13orf1$ ESR2( IGFBP3$ NOG$ RPSAP52$ TREH$
C14orf149$ ETS1$ IGFBP4$ NOS3$ RREB1$ TRIM13$
C14orf181$ ETV6$ IGFBP5( NOV$ RSPO3$ TRIM32(
C14orf39$ EVC( IGFBP6( NPC2$ RTF1$ TRIM37(
C16orf79$ EVC2( IGFBP7$ NPFFR2$ RUNX2$ TRIP11$
C18orf45$ EXOC1$ IHH$ NPPC$ RUNX3$ TRMT11$
C19orf36$ EXOSC5$ IKBKG( NPR2( RYBP$ TRPC4AP$
C1orf105$ EXT1( IL20RB$ NPR3$ SALL1( TRPM5$
C1orf21$ EXT2( IL31$ NSD1$ SALL4( TRPS1(
C1orf86$ FAM101A$ IL31RA$ NSDHL( SAMD3$ TRPV4(
C20orf108$ FAM124B$ IL7$ NSMAF$ SBDS( TSEN15$
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C20orf152$ FAM148A$ IL8RA$ NUCB2$ SBNO1$ TSSC4$
C20orf4$ FAM148B$ INPP5E$ NUDT3$ SCAND1$ TTC27$
C2orf34$ FAM164A$ INS( NUDT8$ SCARB1$ TTC30A$
C2orf44$ FAM173A$ INSR$ NUP160$ SCMH1$ TTC7A$
C2orf54$ FAM184B$ INTS7$ NUSAP1$ SCUBE3$ TTK$
C2orf62$ FAM27L$ IP6K3$ OBSL1( SDCCAG3$ TTLL4$
C2orf79$ FAM46A$ IPPK$ OCRL( SDHA( TTYH3$
C2orf84$ FAM49B$ IRF1$ OFD1( SDHB$ TULP4$
C3orf18$ FAM81A$ IRS1( OIP5$ SDR16C5$ TWIST1$
C3orf31$ FAM82A1$ IRS2( OPN5$ SEC11A$ TXNDC5$
C3orf37$ FANCA( ISCA2$ OPTN$ SEC16A$ UBE2Z$
C3orf63$ FANCB( ITGB8$ OR2K2$ SECISBP2( UBR1(
C3orf65$ FANCC$ ITIH1$ OR2Z1$ SEMA3E( UBXN2A$
C4orf14$ FANCD2( ITIH3$ OR4A5$ SENP2$ UHRF1BP1$
C5orf23$ FANCE$ ITIH4$ OR4B1$ SENP6$ UIMC1$
C6orf1$ FANCF( ITPKA$ OR4C12$ SERAC1$ USE1$
C6orf106$ FANCG( ITPR3$ OR4C13$ SERPINE2$ UTP18$
C6orf125$ FANCI( JAG1( OR4C46$ SERPINH1$ UTP6$
C6orf138$ FANCL( JAK2( OSR1$ SF3A2$ VAMP4$
C6orf15$ FANCM( JAZF1$ OSTF1$ SF3B4$ VANGL2$
C6orf173$ FAR2$ JMJD4$ OTUD4$ SFMBT1$ VDR(
C6orf191$ FARP2$ KAL1( OTUD7B$ SFTA2$ VEGFA(
C7orf11( FBLL1$ KBTBD8$ OTX2( SH3BP2( VGLL2$
C7orf30$ FBLN1( KCNE2$ PACRGL$ SH3GL3$ VGLL4$
C9orf163$ FBLN2$ KCNH2$ PACSIN1$ SHH( VPRBP$
C9orf40$ FBLN5$ KCNIP4$ PADI2$ SHOX( VPS13C$
C9orf41$ FBN1( KCNJ1$ PANK3$ SHOX2$ VTA1$
C9orf64$ FBN2( KCNJ11$ PAPPA$ SHQ1$ WDR66$
C9orf95$ FBXL17$ KCNJ12$ PAPPA2$ SHROOM4( WDR73$
CA2( FBXO7$ KCNJ2$ PAPSS2( SIL1( WISP3(
CA8$ FBXW11$ KCNQ1$ PAQR5$ SIX1$ WNT3(
CABLES1$ FBXW4( KCNRG$ PARN$ SIX2$ WNT7A(
CAGE1$ FCHO2$ KDM5C( PARVA$ SIX3$ WNT9A$
CAMK1D$ FER$ KERA$ PAX3( SIX6$ WRN(
CARD11$ FGD1( KHDRBS3$ PAX8( SKI$ WWC2$
CASKIN1$ FGF1( KIAA0317$ PCBD2$ SLAMF6$ YEATS4$
CASQ1$ FGF10( KIAA0368$ PCCB$ SLC16A7$ ZBTB16(
CATSPER3$ FGF18$ KIAA0586$ PCGF2$ SLC22A18$ ZBTB20$
CBLN3$ FGF2( KIAA1279( PCNT( SLC22A4$ ZBTB38$
CCBL2$ FGF21( KIF1A$ PCSK5$ SLC22A5$ ZCCHC24$
CCDC126$ FGF23( KIF23$ PDE10A$ SLC26A2( ZCCHC6$
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CCDC28B( FGFR1( KIF27$ PDE11A$ SLC29A3( ZFAT$
CCDC3$ FGFR2( KISS1( PDE3A$ SLC2A2( ZFP36L1$
CCDC49$ FGFR3$ KISS1R( PDIA4$ SLC30A10$ ZFYVE26$
CCDC66$ FILIP1$ KRAS( PDLIM4$ SLC34A3( ZMPSTE24(
CCDC78$ FKBP1B$ L3MBTL3$ PEA15$ SLC35C1( ZNF169$
CCDC85A$ FKTN$ LAMC1$ PEG3( SLC35D1( ZNF341$
CCDC91$ FLI1$ LAMC2$ PEX1$ SLC35D2$ ZNF346$
CCDC92$ FLNA( LARGE$ PEX12( SLC37A4( ZNF366$
CCDC99$ FLNB( LASS3$ PEX19$ SLC38A9$ ZNF367$
CCHCR1$ FMO5$ LBR( PEX3( SLC39A13$ ZNF462$
CCNB2$ FNDC3B$ LCORL$ PEX5( SLC4A4( ZNF652$
CCRK$ FOLH1$ LDHAL6B$ PEX6( SLC5A3$ ZNF664$
CD2AP$ FOXC1( LEMD2$ PEX7( SLC6A8( ZNF678$
CD81$ FREM3$ LEMD3( PFN4$ SLCO1B3$ ZNF683$
CDC14B$ FRS2$ LEPRE1( PGP$ SLCO1C1$ ZNFX1$
CDC42EP3$ FSD1L$ LFNG( PHB$ SLFNL1$ ZSCAN2$
CDH3( FUBP3$ LHX3$ PHEX( SLIT2$ ZZZ3$
CDK2AP1$ FUCA1( LHX4( PHF20$ SLIT3$ $
CDKN1C$ G6PC( LIFR( PHF6( SLITRK5$ $
CDKN2AIP$ GAB1$ LIG4( PHLDB1$ SMAD1$ $
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Supplementary Material – Simulation of Finnish population history, 
guided by empirical genetic data, to assess power of rare variant 
tests in Finland 
Supplemental Method 
Fitting Finnish demographic history parameters 
P(data|model) for each model was calculated as below. The first two terms are the probabilities 
of the observed allele frequency spectra of synonymous and missense variants given the 
demographic model being tested. The third term is the probability of the observed 
synonymous/missense ratio. The last two terms calculate the probabilities of the observed allele 
sharing between Finns and NFEs.  
 
s, m: the observed total number of synonymous or missense variants;  
si, mi: the observed number of synonymous or missense variants within the ith frequency 
category; 
pi, qi: the predicted proportion of synonymous or missense variants that fall into the ith frequency 
category; 
ri: the predicted proportion of variants in the ith frequency category that are synonymous; 
ssi, smi: the observed number of synonymous or missense variants within the ith frequency 
category in the Finns that are shared with NFEs; 
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xi, yi: the predicted proportion of synonymous or missense variants within the ith frequency 
category in the Finns that are shared with NFEs. 
 
 
Figure S4.1: Singleton variants in a population of Finns are more likely to be seen again in 
another population of Finns. For the set of singleton variants ascertained from a random 
sample of 250 individuals, we assessed the proportion (y-axis) and the frequencies (x-axis) of 
these variants observed in a second sample of 250 individuals. The analysis was done in 
synonymous (A) and missense (B) variants separately. 
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Figure S4.2: Agreement of empirical missense/synonymous ratios with the modeled ratios.  
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Figure S4.3: Allele sharing between the Finns and the NFEs, comparing simulated data and 
empirical data. For the set of variants ascertained from the first sample, we assessed their 
frequencies (x-aixs) in the first sample and the proportion (y-axis) of these variants observed in a 
second sample. For results in Finns, the first sample is 843 Finns and the second sample is 820 
NFEs; for results in NFEs, the first sample is 820 NFEs and the second sample is 843 Finns. The 
analysis was done in synonymous variants (A) and missense variants (B) separately. 
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Figure S4.4: Variance explained by variants within different frequency ranges under four 
different disease models.  
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Figure S4.5: Number of causal variants (solid lines) or background variants (dashed lines) 
with MAF below 5% per gene, in either 30,000 Finns or 30,000 NFEs. 
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Figure S4.6: Accumulated allele frequency of causal variants (solid lines) or background 
variants (dashed lines) with MAF below 5% per gene, in either 30,000 Finns or 30,000 
NFEs. 
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Figure S4.7: Power difference between using the Finns and the NFEs for genes of different 
τ values under M4 (τ randomly sampled from 0, 0.5, and 1 for each effect gene). Shown here 
is the result for SKAT-O test and the sample size is 30,000. The biggest power gain in the Finns 
is seen among genes with τ value of 1 (almost doubling in power, paired t-test p value < 0.01). 
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Figure S4.8: Distribution of variance explained per gene by variants with MAF below 5% 
under four different disease models in either 30,000 Finns or 30,000 NFEs, for genes 
detected in the Finns only. (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly 
sampled from 0, 0.5, and 1 for each effect gene). 
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Figure S4.9: Distribution of variance explained per gene by variants with MAF below 5% 
under four different disease models, in either 30,000 Finns or 30,000 NFEs, for genes 
detected in the NFEs only. (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly 
sampled from 0, 0.5, and 1 for each effect gene). 
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Figure S4.10 Accumulated allele frequency of causal variants (solid lines) or background 
variants (dashed lines) with MAF below 5% per gene under four different disease models, 
for genes detected in the Finns only. The distributions for causal variants in the Finns shift 
upwards compared to the NFEs. (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ 
randomly sampled from 0, 0.5, and 1 for each effect gene). 
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Figure S4.11 Accumulated allele frequency of causal variants (solid lines) or background 
variants (dashed lines) with MAF below 5% per gene under four different disease models, 
for genes detected in the NFEs only. The distributions for causal variants in the Finns shift 
downwards compared to the NFEs. (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ 
randomly sampled from 0, 0.5, and 1 for each effect gene). 
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Figure S4.12 Distribution of variance explained per gene by variants with MAF below 5% 
under four different disease models, in either 30,000 Finns or 30,000 NFEs. The genes were 
sampled so as to match the variance explained in the Finns and the NFEs. (A) M1 (τ=0); (B) M2 
(τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly sampled from 0, 0.5, and 1 for each effect gene). 
 
 
2.5 3.0 3.5 4.0 4.5 5.0
0.
0
0.
2
0.
4
0.
6
0.
8
−log10(Variance explained per gene)
De
ns
ity
Finn
NFE
A
2.0 2.5 3.0 3.5 4.0
0.
0
0.
5
1.
0
1.
5
−log10(Variance explained per gene)
De
ns
ity
Finn
NFE
B
2.0 2.5 3.0 3.5 4.0 4.5
0.
0
0.
5
1.
0
1.
5
−log10(Variance explained per gene)
De
ns
ity
Finn
NFE
C
2.0 2.5 3.0 3.5 4.0 4.5 5.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
−log10(Variance explained per gene)
De
ns
ity
Finn
NFE
D
 148 
 
Figure S4.13 Accumulated allele frequency of causal variants (solid lines) or background 
variants (dashed lines) with MAF below 5% per gene under four different disease models. 
The genes were sampled so as to match the variance explained in the Finns and the NFEs. (A) 
M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly sampled from 0, 0.5, and 1 for 
each effect gene). 
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Figure S4.14 Power of SKAT-O test in 30,000 Finns or 30,000 NFEs under four different 
disease models, either for all genes, or for a set of genes sampled by matching the variance 
explained in the Finns and the NFEs.  
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Figure S4.15: Power of exome sequencing studies in 30,000 Finns vs. 30,000 NFEs. (A) M1 
(τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ randomly sampled from 0, 0.5, and 1 for each 
effect gene). We simulated a quantitative trait (h2 = 80%) for which aggregated coding variation 
in 1,000 genes explains the total heritability. Models M1-4 were generated by varying the degree 
of coupling (τ) between a causal variant’s phenotypic effect and the strength of purifying 
selection against that variant. We implemented five gene-based tests (T1, T5, MB, VT, SKAT-
O) in addition to the single variant tests (singleVar) (see Methods). 
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Figure S4.16: Agreement of empirical allele frequency spectra with the modeled spectra of 
exome chip data.  
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Figure S4.17: Power of exome chip study vs exome sequencing study in the NFEs under M4 
using SKAT-O test. As different genes are likely to have different pleiotropic effects and are 
therefore exposed to different strengths of purifying selection, M4 is generated to represent a 
potentially more realistic scenario where τ (the degree of coupling between a causal variant’s 
phenotypic effect and the strength of purifying selection against that variant) is randomly chosen 
among 0, 0.5 and 1 for each effect gene. The top two lines show power comparison at a fixed 
sample size; the bottom two lines show power comparison at a fixed cost (and thus only a tenth 
of the samples were sequenced). 
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Figure S4.18: Power of exome chip study (N=30,000) vs exome sequencing study (N=3,000) 
in the Finns under four different disease models. (A) M1: τ=0; (B) M2: τ=0.5; (C) M3: τ=1; 
(D) M4: τ randomly sampled from 0, 0.5, and 1 for each effect gene. 
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Figure S4.19: Proportion of genes detected by exome sequencing (N=30,000) only, or by 
exome chip (N=30,000) only, or by both (using SKAT-O test) under four different disease 
models (M1: τ=0; M2: τ=0.5; M3: τ=1; M4: τ randomly sampled from 0, 0.5, and 1 for each 
effect gene). As τ gets larger, the proportion of genes detected by exome sequencing only 
increases. (A) Results in Finns; (B) results in NFEs. 
M1 M2 M3 M4
0
0.
2
0.
4
0.
6
0.
8
1
exome sequencing only 
discovered by both
exome chip only
Model
Pr
op
or
tio
n 
of
 g
en
om
e−
wi
de
 si
gn
ific
an
t g
en
es
A
M1 M2 M3 M4
0
0.
2
0.
4
0.
6
0.
8
1
exome sequencing only 
discovered by both
exome chip only
Model
Pr
op
or
tio
n 
of
 g
en
om
e−
wi
de
 si
gn
ific
an
t g
en
es
B
 155 
 
 
Figure S4.20: Distribution of variance explained per gene by variants with MAF below 5% 
in exome sequencing (solid line) or exome chip (dashed line) data of 30,000 Finns, under 
four different disease models. (A) M1 (τ=0); (B) M2 (τ=0.5); (C) M3 (τ=1); (D) M4 (τ 
randomly sampled from 0, 0.5, and 1 for each effect gene). 
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Figure S4.21: Power of two different exome chips in the Finns under M4 (τ randomly 
sampled from 0, 0.5, and 1 for each effect gene) using SKAT-O test. One chip design 
resembles that of the actual exome chip design (top line); the other chip design uses NFE 
samples only with no contribution from Finnish samples (bottom line). 
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Figure S4.22: MDS plots of whole exome sequenced samples from GoT2D project. (A) 
Finns (N=843); (B) NFEs (N=820). 
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Table S4.1: Variants found in both samples tend to have higher allele counts in Finns 
 
Finn-NFE Finn-Finn NFE-NFE Variants 
Difference p value Difference p value Difference p value 
Synonymous  0.415 0.000733 0.00451 0.911 0.0059 0.845 
Missense  0.505 1.43e-06 0.00868 0.777 0.000157 0.994 
  
For Variants shared between 250 Finns and 250 NFEs, their allele counts tend to be higher in 
Finns (paired t-test). As controls, we also checked allele counts for variants shared between 250 
Finns and another 250 Finns, as well as between 250 NFEs and another 250 NFEs.  
 
 
 
 
Table S4.2: Birth place distribution of FUSION samples 
 
Birth place No. of samples 
UUSIMAA, UUDENMAAN / NYLAND 27 
TURKU-PORI, TURUN JA PORIN / ABO-BJORNEBORG, ABO-
OCH-BJORNEBORG 
92 
HAME, HAMEEN / TAVASTEHUS 105 
KYMI, KYMEN / KYMMMENE, VIBORG, VIIPURI 49 
MIKKELI, MIKKELIN / SAINT MICHEL 61 
POHJOIS-KARJALA, POHJOIS-KARJALAN / NORRA-KARALEN, 
NORRA KARENS 
52 
KUOPIO, KUOPION / KUOPIO 148 
KESKI-SUOMI, KESKI-SUOMEN / MELLERSTA-FINLAND 76 
VAASA, VASAAN / VASA, WASA 125 
OULU, OULUN / ULEABORG 41 
LAPPI, LAPIN / LAPPLAND 13 
KARJALA, VIIPURI (area formerly part of Finland) 54 
Total 843 
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Table S4.3: Three different models of Finnish population history 
 
Parameters Class 1 Modela Class 2 Modelb Class 3 Modelc 
Bottleneck size 200-4000 1000 1000 
Bottleneck time 1.5-3.5ky ago 2.5ky ago 2.5ky ago 
Growth rate (per 
generation) 
2.5-10% 5-10% Slow phase:0.5-5% Fast 
phase: 8-30% 
Gene flow into Finns 0 1-5% 0.5-7% 
Minimal   
-log(P(data|model)) 
1419 426 267 
aFounding bottleneck event followed by exponential growth of constant growth rate, with no 
gene flow between NFEs and Finns 
 
bFounding bottleneck event followed by exponential growth of constant growth rate, with gene 
flow from NFEs into Finns 
 
cFounding bottleneck event followed by a slow growth phase and a fast growth phase, with gene 
flow from NFEs into Finns 
 
